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QUANTIFICATION OF FLOW PARAMETERS IN COMPLEX 
VASCULATURE FLOW PHANTOMS USING CONTRAST-ENHANCED 
ULTRASOUND METHOD 
ASAWARI PAWAR 
ABSTRACT 
Currently, there are few simple-to-construct in vitro, wall-less phantoms that have 
accurate acoustic properties while mimicking the complex normal and neoplastic 
geometries of the vascular network. The purpose of this study was to develop agar-based 
tissue-mimicking phantoms (TMP) to model such networks and to quantify the mean 
intensity and the slope measurements of the ultrasound flow. Three types of vascular 
networks were developed; (1) single vessel, (2) multi-vessel with artery bifurcations and 
(3) multi-vessel with artery bifurcations and structural abnormalities typical of diseased 
(tumor) vascular networks. Bolus injections of ultrasound contrast agents (UCAs) were 
performed under varying flow conditions relevant to our ongoing work in developing 
techniques to simultaneously quantify both the total volume and flow measurements 
within a tumor phantom 
The correlation coefficient between the mean slope measurements and the least squares 
fitted line was all higher than 0.95, indicating a good linear relationship between the 
mean slope and the flow-rates. For all single-vessel flow phantom data, the mean 
proportional difference of the slope measurements and flow-rate was 0.695 ± 0.18 (mean 
± SD). It was found that the correlation coefficient between the mean slope 
vi 
 
measurements and the least squares fitted line is 0.90, indicating a good linear correlation 
between the single-vessel and Multi-vessel flow phantoms. However, the parameters 
obtained from tumor region 1, 2 and 3 did not show any significant flow pattern and 
correlation after contrast injection of UCAs.  
Finally, the slope measurements of intensity at the tumor regions in-flow and out-flow 
demonstrated the nonlinear and undefined relationship between the measured intensity 
and varied flow-rates. Ideally, most information could be obtained when intensities at 
both the input and the output of the tumor periphery are measured. For further studies, 
alternative modeling of the problem is required because in physiology, microvasculature 
flow system has multiple input vessels and multiple output vessels. Developing new 
time-intensity-based techniques is the focus of future research. 
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CHAPTER I 
INTRODUCTION 
  
 
 Quantitative assessment of vascular blood flow has been a topic 
of significant interest for research for many years [1–5]. Blood flow is a 
physiological parameter of clinical importance because it reflects the adaptive 
response of organs. This response is to either their normal biological environment 
or to disease, trauma, and the malignant progression of cancer [6-7]. Disruption of 
flow outside the normal range can pose serious consequences for local tissue and is 
therefore an indicator of a number of diseases, including cancer and diabetes [5, 8 
and 9], ischemic heart disease, stroke and cancer. Typical clinical techniques aimed 
at monitoring flow are Doppler ultrasound [10, 11], laser speckle [12–14], photo-
acoustic tomography [15] laser Doppler [16, 17], autocorrelation methods [18], and 
Doppler optical coherence tomography [4, 19]. Contrast enhanced ultrasound offers 
a unique method to quantify the blood to measure the flow, perfusion, vascular 
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volume and morphology of micro vascular networks. The technique relies on the 
time intensity method; after the injection of the indicators, their concentration is 
monitored as a function of time, generating a time intensity curve (TIC) from which 
a series of quantitative flow parameters is extracted and analyzed from this time 
intensity curves [20, 21]. This is also known as dye-dilution theory.  Calibration and 
validation of these methodologies and techniques have been conducted primarily 
with simple phantoms mimicking a single blood vessel or vascular bed [13, 16, and 
23]. 
Generally, they comprise i) one or three silicon intertwined tubes immersed in a 
custom made water tank that mimics the biological environment surrounding the 
vasculature of interest or ii) dialysis cartridge containing with capillaries dimension 
to that of one type of vessel found in the micro vascularization (arteriole diameter < 
300 μm) [22]. The intertwined silicon tubes or the dialysis cartridge was connected 
to a peristaltic pump or other mechanical pumping system so as to accurately 
control the flow rate in the artificial vascular structure. In these studies techniques 
were based on pumping a fluid through a phantom placed in a water tank. Results 
showed that several parameters derived from the time-intensity curve had a good 
correlation with the flow rate under certain conditions [23]. 
In vitro studies done by other research groups were also based on a 
volumetric tumor assessment model [24]. There have been many studies recently 
published which implement ultrasound imaging techniques for monitoring disease 
state by way of blood flow characterization. Some of these strategies seek to 
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quantify the amount of vascularization within the tissue by using Doppler 
techniques [25-28]. Other strategies attempt to extract information about the 
rates at which blood flows through the tissue using contrast-based destruction-
reperfusion (or “flash replenishment”) techniques [29-34]. Additionally, others have 
attempted to extract quantifiable metrics for vessel and vessel network structure as 
a means to understand disease progression [33, 35-37]. Vessel tortuosity, which is a 
morphological abnormality exhibited by cancerous vasculature in both humans 
[38], and has been used as a marker for disease state and therapeutic response in 
clinical studies based on image-derived data [39, 40]. The abnormal 
pathophysiology and micro vascular structure gives rise to temporal and spatial 
variations in ultrasound signal enhancement that differs from normal surrounding 
tissue [41], which can be used to provide information on tumor characteristics [42]. 
One of the major shortcomings of these studies is the lack of a robust, reliable, easily 
reproducible and stable phantom for quantification and evaluation of blood flow in 
complex vasculatures. The vascular flow phantoms for ultrasound imaging are 
needed to [43]: (i) be compatible with the imaging modalities evaluated, i.e., it is 
important that the materials involved in the construction of phantoms allow clearly 
the identification of the shape of the vessel lumen on the images, with no or 
minimum artifacts. (ii) Be anthropomorphic, i.e., their geometry should mimic as 
close as possible the complexity of real human vessels [44]. (iii) The individual 
materials used in their construction should have similar acoustic and mechanical 
properties to soft tissue, vessel tissue and blood in order to avoid artifacts and allow 
for meaning measurement of blood flow [44] (iv) In case of constructing a tumor 
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vascular phantom the techniques used to split the flow should be such that the fluid 
flows slower at the downstream.  However, the above studies did not focus on 
developing phantoms with vascular abnormalities combined with flow simulation 
for quantification of flow parameters, which would otherwise be challenging to 
construct. On the pathway to developing vascular phantoms, numerous materials 
have been reported to mimic the vessel wall in these flow phantoms including: glass, 
plastic, Teflon, latex, C-flex, heat shrink and neoprene [45] with suitable properties 
for use due to their availability in tube form in ultrasound phantoms. However these 
materials tend to produce significant distortion of ultrasound due to its high 
attenuation. Additionally, these materials are only commercially available with fixed 
dimensions and therefore they are not suitable for use in mimicking the complex 
vessel shapes such as curvatures, bifurcations, blockages, etc. which are necessary 
in anatomically realistic flow phantoms. To overcome these problems some 
researchers have used excised human vessels removed during either autopsy or 
endarterectomy, but this method is not ideal due to both lack of availability, ethical 
issues, and differences in acoustic properties between living and dead tissues. Some 
have attempted to mimic large vessels [46], such as the carotid artery [47]. Other 
studies have sought to create a vascular phantom using real vessels harvested from 
cadavers [48, 49]. Some of the major limitations of these designs are the size of the 
vessels and the absence of a leaky state, where small contrast agents may traverse 
between the mimicking vascular and tissue types. The ideal solution lies in the 
development of phantoms with no vessel walls, known as ‘wall-less’ vascular flow 
phantoms in which vessels are constructed by molding different vessel shapes 
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within a tissue mimic substance known as agar [50]. In this case, the blood 
mimicking fluid is in direct contact with the TMM. Wall-less flow phantoms resolve 
the problems of vessel wall attenuation and impedance mismatches, and thus also 
possible to develop variety of vessel geometries such as curves, bifurcations, 
trifurcations, tumors, etc. Our simple fabrication procedure allows us to tailor three 
different types of vascular phantoms with acoustic properties of the vascular 
material to values relevant for studies of biological tissue, which would provide a 
system through which blood-mimicking fluid can be pumped to provide a realistic 
reproduction of flow conditions to be able to quantify the blood flow in complex 
vasculature. 
The purpose of this study is to design and fabricate a fast prototyping of 
phantoms simulating a superficial vasculature network, which would provide a 
system through which blood-mimicking fluid can be pumped to provide a realistic 
reproduction of flow conditions in the relevant vascular territories.  The second aim 
was to quantify the flow through these phantoms to determine the time-intensity 
curves to calculate the slope, intensity and the velocity of the flow. The third aim 
was to further investigate the phantoms in conjunction with radiological imaging 
modalities, such as Computed Tomography (CT) to determine the relative change in 
diameters comparative to ultrasound (US) measurements. 
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CHAPTER II 
BACKGROUND 
 
 
2.1 The Circulatory System  
2.1.1 General Description 
The circulatory system consists of three independent systems that work 
together: the heart (cardiovascular), lungs (pulmonary), and arteries, veins, 
coronary and portal vessels (systemic). The microcirculation is responsible for the 
distribution of blood within tissues, and describes the blood flow throughout the 
microvasculature, which is comprised of arterioles, capillaries, and venules. Healthy 
blood flow is responsible for sustaining a healthy environment for the individual 
cells of all organs and tissues (Fig 1). The primary function of the microcirculation is 
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the delivery of nutrients and oxygen and the removal of waste products and carbon 
dioxide [51-53]. Other functions include the regulation of blood pressure and body 
temperature [54]. Blood transports oxygen, carbon dioxide, nutrients, waste, heat, 
hormones, and agents of the immune system. The system is responsible for the flow 
of blood, nutrients, oxygen and other gases, and as well as hormones to and from 
cells. An average adult has 5 to 6 quarts (4.7 to 5.6 liters) of blood [55], which is 
made up of plasma, red blood cells, white blood cells and platelets. The system of 
blood vessels in the human body measure about 60,000 miles (96,560 kilometers) 
[55]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Organizational structure of the microcirculation thought of as a tree-type 
network of arterioles that leads into an anastomosing network of capillaries [55] 
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2.1.2 Normal Vasculature 
Blood flows throughout the body tissues in blood vessels. An extraordinary 
degree of branching of blood vessels exists within the human body. There are three 
major types of blood vessels: arteries, capillaries and veins.  The microcirculation 
begins when small arteries of around 100 μm in diameter begin to branch into 
smaller arterioles, which have diameters of around 20-30 μm [52, 53].  
Blood that passes through the arterioles will enter the capillaries (7-10 μm in 
diameter), where the majority of nutrient and gas exchange takes place. There is 
considerable branching taking place on the capillary level which serves to supply 
every tissue cell in the body. This is evidenced by the fact that all tissue cells are 
located within 60-80 μm of a capillary [52]. The blood is collected from capillary 
beds by venules, which may vary in size and character, but on average have an 
internal diameter roughly around 20 μm [53]. The organizational structure of the 
microcirculation may be thought of as a tree-type network of arterioles that leads 
into an anastomosing network of capillaries. This capillary bed is made up of a 
dense network of parallel-running vessel branches that eventually leads back into a 
network of venules of similar structure to that of arterioles [56]. 
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2.2 Diseased Microcirculation 
2.2.1 General Description 
The early manifestations of diseases can be encountered in microcirculation. 
The failure to cope with major changes in circulatory hemodynamics, the presence 
of abnormal blood components, a change in the control of micro vascular resistance, 
or abnormalities in the endothelial barrier function can all lead to microcirculatory 
diseases. Some of the diseases that damage the microcirculation itself or the blood 
includes infection, diabetes, hypertension, ischemia, sickle cell disease, etc. Some 
diseases lead to structural damage of essential components of the microcirculation 
such as hypertension and abnormal angiogenesis as in the case of cancer. Cancer is 
the second largest killer in the industrialized world, after cardiovascular disease, 
and is responsible for about 25% of all deaths in North America [57]. 
Consequently, qualitative and quantitative examination of in-vivo 
microcirculation and microvasculature in both normal and diseased tissues has 
been the subject of intense research in both clinical and laboratory settings [58]. 
The microcirculation plays an important role in cancer development and 
progression [42], and examining tumor microvasculature may provide diagnostic 
and prognostic information regarding the disease.  
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2.2.2 Angiogenesis  
Angiogenesis, by definition, is the formation of new capillary blood vessels 
from pre-existing micro vessels [59]. Thus, in order for tumors to grow rapidly, 
angiogenesis must be initiated [60]. Tumors begin when a group of cells display 
uncontrolled cell growth [61]. They are described as benign when the growth is 
relatively slow and constrained to a specific location. Malignant tumors, on the other 
hand, grow much more rapidly and may undergo a process called metastasis [59, 
60], whereby the tumor cells may disperse to another tissue or organ and establish 
secondary tumors. The term cancer generally refers to malignant tumors [52]. A 
tumor will begin supporting itself through avascular means, meaning the diffusion 
of nutrients and oxygen will support its growth. This continues until the tumor 
reaches a certain size, roughly 1 mm3 [62]. Any growth of the tumor after it has 
reached its maximum size through avascular means would require the recruitment 
of blood vessels to deliver the necessary nutrients and oxygen [63]. As cell growth 
continues, the microenvironment surrounding the tumor becomes critically hypoxic 
due to an exhaustion of local oxygen supply. This ‘stressed state’ stimulates a 
cascade of biological events that eventually form a dedicated tumor 
microvasculature (Fig. 1.2) [62]. In contrast to the self-limiting processes that occur 
during normal angiogenesis, tumor angiogenesis is wildly uncontrolled. Once a 
small avascular mass recruits a dedicated blood supply, a positive feedback loop is 
created, driven by progressive tumor growth and a chronic state of hypoxia and 
acidosis [64, 65]. This neovascularization is a process described as angiogenesis, 
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and has been identified as an essential step for tumor growth [63]. The tumor 
vasculature that arises, however, is much different than normal vasculature. 
 
2.2.3 Tumor vascular  
The rapid development of tumor vasculature by abnormal and poorly 
controlled angiogenesis results in vessel walls with pores ranging in size from 200 
nm to 2 µm, with an average pore size reported to be approximately 400 nm [60, 
163]. The leaky tumor vasculature, owing to the presence of these pores, allows 
macromolecules and nanoparticles to preferentially extravasate into the tumor in 
contrast to healthy blood vessels. Tumor vasculature is highly heterogeneous, 
where the vessels are irregularly constricted or dilated, can have uneven diameters, 
and excessive branching [66]. Tumor vascular networks consist of a disorderly 
tangle of tortuous and leakier than normal vessels with random orientation. Tumor 
vascular networks display loops, shunts, blind pouches, trifurcations, large 
avascular areas and lack of hierarchy (Figure 1.3a) [66-70, 71, and 72].  Tumor 
vascular networks differ significantly from normal tissue. Whereas normal vascular 
networks are well ordered with a hierarchical vessel arrangement, tumor vascular 
networks can be described as tangle of vessels [73] (Figure 1.2). They also show 
absence of differentiated arteries and veins. The molecular mechanisms that cause 
abnormal vascular characteristics are not well understood, but imbalance of pro- 
and anti-angiogenic factors is considered to be a key contributor [74]. Alongside the 
morphological abnormalities of an individual tumor, the distribution of regional 
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blood flow is equally heterogeneous in space and irregular in time, often 
demonstrating abnormal oscillations and even reverse flow patterns.  
 
3.3 Techniques to measure Microcirculation Blood Flow 
Modern computing power and recent advances in the field and technology of 
molecular genetics has led to an explosion of potential therapeutic targets and drugs 
for the early detection of cancer and its treatment. Generally, meaningful changes in 
tumor size are delayed up to 6 to 8 weeks after the initiation of therapy. An 
improved approach is needed to assess the behavior and response of a cancer 
vasculature at an earlier stage of treatment. Compared to normal tissue, many 
tumors have high micro vessel densities, large blood volumes, and unique and 
heterogeneous perfusion characteristics as discussed earlier. In an early trial of the 
anti-angiogenic drug bevacizumab for human colorectal cancer, the treatment was 
shown to decrease colorectal tumor blood perfusion, blood volume, and blood flow 
and tumor interstitial fluid pressure [31]. Currently there exist a number of clinical 
imaging technologies that can be used to assess features of the microvasculature as 
discussed below. 
The basic principles of all medical imaging modalities involves the 
interaction of some form of energy (magnetic, radiation, optical, acoustic) with 
tissue and cellular structures within the body; whether it be magnetic resonance 
imaging (MRI), computed x-ray tomography (CT), positron emission tomography 
(PET), optical coherence tomography (OCT), or ultrasound (US). 
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2.4 PRINCIPLES OF ULTRASOUND IMAGING 
Ultrasound imaging is a diagnostic imaging tool for visualizing and assessing 
physiological structures with real time images. Ultrasound waves begin with the 
transducer, typically a piezoelectric material, where an electrical pulse is converted 
to an ultrasound pulse and vice versa [75]. The ultrasound pulse is comprised of a 
modulated sinusoidal carrier signal, typically at the resonant frequency of the 
transducer. As the ultrasound pulse travels through tissue, interactions with 
boundaries between tissues of different acoustic impedance will cause some of the 
energy of the pulse to reflect back towards the transducer. 
  
Figure 2: Ultrasound imaging as a diagnostic imaging tool for visualizing and 
assessing physiological structures with real time images [75] 
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As shown in schematic diagram figure 3, due to the natural characteristics of 
piezoelectric, the reflected ultrasound energy that returns to the transducer is 
reconverted back into an electrical signal, which is processed and displayed as an 
image on the screen. The conversion of sound to electrical energy is called the 
piezoelectric effect. The image can be displayed in a number of modes: 1) amplitude 
(A) 2) brightness (B) 3) motion (M).  
Depending on the speed at which sound travels through the tissue, the 
returning echo will arrive at the transducer after some time delay (td), [41] which is 
proportional to the depth of the scattering boundary: 
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Figure 3: the natural characteristics of piezoelectric making the reflected 
ultrasound energy that returns to the transducer to reconvert back into an electrical 
signal which is processed and displayed as an image on the screen [41] 
 
Ultrasound travels through a medium as a longitudinal vibration of the 
medium's particles, where the particles of the medium can be envisioned as 
connected by springs, effectively making the medium elastic. In a linear 
approximation, the propagation speed of the ultrasound wave (co) will be dictated 
by the medium properties, and is determined by 
 
   √
 
 
 
where, β is the bulk modulus and ρ is the density. The speed of sound in water is 
approximately 1485 m/s, and ranges between 1450 m/s to 1600 m/s depending on 
the tissue type. The ultrasound wavelength (λ) is then determined by the speed of 
sound (co) and particular frequency (f)  
𝜆 = 𝑜/𝑓 ∙  
The number of wavelengths in an ultrasound pulse dictates spatial pulse 
length. An ultrasound imaging pulse is typically two or three cycles long [76] and 
shaded by a Gaussian envelope. The ability to resolve fine details and objects is 
governed by the spatial resolution of our imaging system (Figure 4). The axial 
resolution of an ultrasound system refers to its ability to distinguish between two 
closely spaced objects in the beam direction or axis [76]. In order to achieve good 
axial resolution, the returning echoes from distinct reflectors should not overlap. 
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Thus, since the distance traveled between two reflectors by a pulse is twice the 
distance between those reflectors, the axial resolution (AR) is 
    
 
 
                          
 
where, H is number of cycles in the pulse x wavelength. The lateral resolution 
describes the ultrasound systems ability to distinguish between two closely spaced 
objects perpendicular to the beam direction, or orthogonal to the axial direction, in 
the imaging plane [76]. This lateral resolution is determined by the imaging 
wavelength, such that higher frequencies yield higher lateral resolution.  The 
elevation resolution, or the slice thickness of the ultrasound beam, is dependent on 
the height or focusing of the transducer elements or orthogonal to the axial 
direction, out of the imaging plane. 
 
Figure 4: Ultrasonic beam resolution [76] 
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An ultrasound pulse may experience many interactions due to the acoustic 
properties of tissue. The energy of the ultrasound beam may be scattered or 
absorbed. Objects within tissue that are roughly the same or smaller in size to the 
wavelength, and scatter ultrasound in all directions cause acoustic scattering. This 
type of scattering is termed non-specular reflection. Specular reflection, on the other 
hand, occurs at the smooth boundaries of regularly shaped objects and reflects 
ultrasound according to Snell’s Law [41]. 
 
 
2.4.1 Dynamic Contrast Enhanced Ultrasound (DCE-US)  
In a typical single capillary, the flow velocity is about 0.3 mm/s, the vessel 
diameter about 5 μm, and the flow rate less than 1 ml per year [77]. These extreme 
characteristics make imaging and quantifying the microcirculation a significant 
challenge. Directly visualizing the microvasculature in situ is impossible, given the 
resolution limits of clinical imaging. Most conventional ultrasound methods are not 
sensitive to vessels smaller than 100 μm [78].  Dynamic contrast enhanced 
ultrasound (DCE-US) is an ultrasound-based method that relies on micron-sized 
bubbles of contrast agents to improve the backscatter of blood. Pharmacokinetic 
models are therefore used to relate the behavior of the contrast agent with 
physiological properties. DCE-US has enabled an assessment of micro vascular 
structures and hemodynamic characteristics.  
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Microbubbles, typically around 1-10 μm in diameter [79], are composed of a 
gas core surrounded by a shell layer. Shells can be composed of albumin, lipid, or 
polymer layers encompassing a gas such as nitrogen or a perfluorocarbon. The 
properties and materials of ultrasound contrast agents and their application are 
discussed in further detail in the following section. The high impedance difference 
due to the liquid-gas surface that separates the microbubble from blood causes a 
strong backscattered echo compared to red blood cells, allowing increased detection 
from blood. Contrast-enhanced ultrasound imaging, usually done at low acoustic 
power in order to minimize microbubble disruption, may employ another technique 
known as a ‘harmonic imaging mode’, whereby the fundamental frequency is 
blocked using a frequency filter set to retain the backscattered harmonic echoes 
generated by resonant modes of the microbubbles. Other techniques, referred to as 
multi-pulse techniques, have been introduced in a ‘pulse-inversion mode’ [79], 
which involves multiple pulses of different amplitude and phase. The combination of 
the echo responses due to these pulses results in the suppression of linear signals 
while retaining odd harmonics of the nonlinear signals. An example of such a 
technique is pulse-inversion [80]. Thus, a dynamic CE-US imaging exam allows 
assessment of blood flow on a microscopic and macroscopic level. The recorded 
data allows qualitative and quantitative assessments to be made by analyzing the 
temporal kinetics of the signal enhancement due to the microbubbles contrast 
agents [81-84]. 
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2.4.2 DCE CT - Dynamic Contrast Enhanced Computed Tomography  
Computed tomography (CT) is an image reconstruction technique that 
assimilates projection type data, acquired from multiple spatial orientations, into a 
high resolution cross sectional image [85]. Although the method can be applied to 
projection data from any modality, clinically, CT generally refers to imaging with x-
rays. X-ray imaging is based on the absorption of high-energy photons by tissues 
and structures with variations in atomic number and density. The most common 
intravenous CT contrast agent is iodine, whose atomic number (N = 53) is twice that 
of calcium (N = 20). Iodine is routinely used to opacify and enhances the 
visualization of major vessels (e.g. surrounding the heart) during angiography [86], 
aid the detection of cancers in the brain and abdomen, and quantify flow and 
perfusion in tissue [87]. Pharmacokinetic modeling of CT contrast agents shares 
similarities with DCE-US perfusion techniques. Contrast enhanced CT utilize 
differences in lesion blood flow for detection and characterization. Due to their very 
slow flow rates, most clinically significant lesion blood flow is not detectable by 
ultrasound, using current Doppler techniques. However, microbubbles enable 
ultrasound to visualize this same information that CT is providing, with improved 
temporal and spatial resolutions. In addition, ultrasound contrast can be used for 
the characterization of lesions by providing additional vascular information not 
available with CT. Unlike contrast enhanced CT, ultrasound tracer concentration can 
capture the whole bolus with higher temporal and spatial resolutions, yielding new 
information about the lesion vascular morphology and blood flow dynamics. A 
major disadvantage of x-ray techniques is the potentially harmful effects of 
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radiation and acquisitions are restricted to a few snapshots of the bolus passage 
(usually 30 sec, 60 sec, 3-10 minutes). For example, a typical 30 cm long chest CT 
(64 slices x 0.6 mm thickness) delivers an effective radiation dose of approximately 
6.0 mSv, three times the yearly dose from our natural environment [88, 89]. The 
sensitivity of ultrasound contrast has been shown to be similar to that of CT for 
metastases [90].  
 
2.5 CONTRAST AGENTS  
The first reported use of bubbles to enhance medical ultrasound was in 1968, 
when Gramiak and Shah noticed a sonographic enhancement in the aortic root 
following an intra-arterial injection of agitated saline [91]. This motivated research 
into smaller bubbles that could remain in the vasculature.  A schematic structure of 
the biomedical microbubble is presented in Figure 5 [164].  
 
Figure 5: Cartoon figure showing structure of a typical microbubble with different 
shell compositions. Microbubbles used for biomedical purposes are typically 
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between 0.5 and 10 μm diameter (the upper limit for passage through the lung 
capillaries) [165] 
 
The gas core is a single chamber and comprises a large majority of the total 
particle volume. The shell acts as a barrier between the encapsulated gas and the 
surrounding aqueous medium. Different shell materials may be used, including lipid 
(~3 nm thick), protein (15–20 nm thick) and polymer (100–200 nm thick). The lipid 
molecules are held together through physical force fields, such as hydrophobic and 
van der Waals interactions. The protein is cross-linked by covalent disulfide bonds. 
The polymer chains are covalently cross-linked and/or entangled to form a bulk-like 
material. 
Microbubbles are gas-liquid emulsions consisting of a gaseous core 
surrounded by a soft or hard shell. The gas core can be air or heavier gases such as 
perfluorocarbon (PFC), while the outer shell can consist of a variety of substances 
including albumin, polymers or a lipid bilayer [92-95]. The enhancement was 
attributed to the large discrepancy between the compressibility of the gas bubbles 
and the surrounding fluid. Microbubbles larger than RBCs would be trapped in the 
capillaries, and submicron- size microbubbles scatter ultrasound poorly and have 
insufficient stability. Like other contrast agents, microbubbles are injected 
intravenously, however due to their sizes of several microns (usually ranging 
between 1 and 4 μm; slightly smaller than red blood cells) confining them to the 
intravascular space (figure 6).  
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Figure 6 shows different ultrasound contrast agents and their distribution 
relative to the vascular endothelial cells. A: Schematic representation of different 
micro- and nanoparticles and their size ranges. Microbubbles are typically 
composed of a phospholipid shell encapsulating a gas, such as perfluorocarbon 
(PFC) and total size ranges from 1-4 μm. B: Microbubbles due to their size are 
restricted to the intravascular space. Targeted microbubbles interact with target 
ligands on the endothelium. Smaller nanoparticle contrast agents are able to 
extravasate through the endothelium and enter the extravascular space, which 
opens up possibilities for targeting extra-luminal molecules. 
 
Figure 6: Different ultrasound contrast agents and their distribution relative to the 
vascular endothelial cells [95] 
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2.5.1 Microbubble Material Preparation 
Shell Material and Gas 
The gas core comprises most of the particle volume and provides the 
mechanism for ultrasound backscatter and drug delivery. Gas bubbles of this size in 
aqueous media are inherently unstable owing to surface tension effects [97] and 
therefore require a stabilizing shell. The shell may be composed of surfactants, 
lipids, proteins, polymers, or a combination of these materials. Because the interior 
gas is a poor solvent for drug molecules, loading strategies must be employed within 
or onto the shell [96]. After the microbubble is prepared and administered in vivo, 
the primary role of the shell is to maintain microbubble integrity [166]. 
Protein Shells 
The first albumin microbubble formulation to be approved by the US Food 
and Drug Administration (FDA) was Albunex (GE Healthcare). An Albunex 
suspension consists of roughly 7x108 microbubbles/mL with a size range from 1 to 
15 μm diameter [98] and could pass the lung capillaries and provide contrast in the 
left ventricle of the heart. Albunex with an air bubble core, was made by sonication 
of albumin solution (so its shell consists of denatured albumin) [96] and is stable 
upon refrigeration for at least two years.  
Surfactant Shells 
Microbubbles stabilized by mixtures of the synthetic surfactants SPAN-40 
and TWEEN-40 were formulated by Wheatley et al [99, 100]. These particular 
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microbubbles were not stable upon dilution, and therefore have limited biomedical 
utility. 
Lipid Shells 
Lipid-coated microbubbles are one microbubble formulations approved for 
clinical use in the US and abroad, including Definity (Lantheus Medical Imaging) and 
Sonovue® (Bracco Diagnostics). Lipid shells have several advantages. Phospholipids 
spontaneously self-assemble into a highly oriented monolayer at the air-water 
interface, such that their hydrophobic acyl chains face the gas and their hydrophilic 
head groups face the water [96].  
Polymer Shells 
These types of microbubbles are stabilized by a thick shell comprising cross-
linked or entangled polymeric species [96]. The bulk nature of the polymer shell 
makes it more resistant to area compression and expansion than its lipid and 
albumin counterparts, which reduces the echogenicity and drug delivery activity. 
Gas core: 
Early CEUS formulations were air filled and lasted in the circulation for less 
than 1 minute. Later, Insoluble gases such as sulfur hexafluoride and 
perfluorocarbons C3F8 (perflutren), C4F10 (perflubutane), C5F12 (perflenapent), 
and C6F14 (perflexane) were used that extended microbubble blood recirculation 
time from seconds to minutes, which was important for targeting efficacy. One of the 
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studies shows that, one C4F10 formulation, BR38, is reported to have circulation 
half-life in mice of nearly 10 minutes [101]. 
 
2.5.2 Detection of Microbubbles UCAs 
Microbubbles are detectable by ultrasound because they have unique 
acoustic property to oscillate non-linearly when exposed to typical clinically used 
ultrasound pulses with frequencies ranging between 2 and 10 MHz that coincide 
with the resonance frequencies of most contrast microbubbles [102-104]. In 
contrast, surrounding tissue structures do not or only minimally show non-linear 
behavior and give rise to echoes that simply mirror the incident ultrasound pulse.  
 
2.5.2.1 Non-linear behavior of Microbubbles 
When ultrasound is exposed at very low mechanical index (MI 0.08-0.3), the 
microbubbles start to oscillate giving rise to a non-linear response contrasting the 
linear response of the myocardial tissue at high mechanical index. Ultrasound 
generates acoustic wave of positive and negative (sinusoidal) pressures. When this 
wave encounters microbubbles, they undergo compression at positive of ultrasound 
wave and expansion at negative of ultrasound wave. This results in an asymmetric-
nonlinear bubble oscillation as shown in the figure pp.  This asymmetry produces 
harmonics, which can be utilized to enhance the signals from the bubbles and 
effectively distinguish them from the surrounding tissue, thus improving the 
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imaging capabilities. Contrast specific ultrasound imaging modalities remove the 
linear tissue response and enhance the contrast microbubble response. There are 
different techniques developed such as the power modulation, pulse inversion or 
coherent contrast imaging to emphasis the contrast microbubbles acoustic signals 
and filter the tissue signals which substantially increases signal-to-background 
ratios which allows detection of small amounts of accumulating microbubbles [105]. 
High mechanical index imaging causes microbubble destruction known as 
destruction replenishment imaging or flash imaging (Fig 7) [165]. In this process 
bubbles within a plane are destroyed, allowing the ultrasound intensity as a 
function of time to be determined upon immediate replenishment of bubbles. By 
high mechanical index triggered imaging, myocardial perfusion can be assessed. 
Low-mechanical index imaging is the most commonly used modality, often 
combined with a high-energy ultrasound flash causing microbubble destruction. By 
this technique real-time contrast echocardiography with simultaneous assessment 
of myocardial function and perfusion can be performed.  
 
Figure 7: Physical mechanisms underlying the biological effects induced when 
microbubbles are excited by ultrasound energy [165] 
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The increase in the applications for UCA has stimulated research and 
development in UCA synthesis in both industry and academia [106-108]. Currently, 
more than five commercial UCAs are available for clinical use, and more than 20 
potential UCAs as listed in the table 2 have been tested around the world. Targeted 
UCAs are also commercially available [109-111]. Additionally, a number of different 
ways to synthesize UCAs using various shell materials and internal gas have been 
published [112-114]. 
We investigated a simple method to synthesize UCAs in our laboratory and 
then evaluated the properties of it. The synthesized UCAs were analyzed by high-
resolution optical microscopy to confirm bubble formation. Bubble size 
distributions in aqueous solution were analyzed with an automated cell counter 
(Invitrogen™ Countess™ II FL Automated Cell Counter). Light microscopy confirmed 
the particle size distribution. The responses to ultrasound imaging and the stability 
of the synthesized UCAs were quantitatively studied by ultrasound imaging over a 
two-week period. 
 
2.5.2.2 Relevant Studies 
UCAs have broad array of applications beyond imaging, including targeted 
high-intensity focused ultrasound (HIFU), drug delivery and drug delivery through 
the blood brain barrier (BBB) [115-119]. The nonlinear response of UCAs to the 
ultrasound field can cause localized micro streaming or jet streaming accompanied 
by cavitation, allowing for alterations in the permeability of the skin, cell membrane, 
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and BBB without significant damage to normal tissue [120-122]. This effect can be 
used to facilitate drug delivery to a localized area [123-126]. Lately, targeted drug 
delivery has been made more plausible by attaching ligands to the UCA shell [117, 
118, and 127-31]. On the other hand, the use of UCAs during HIFU can reduce the 
energy required to damage cancerous tissue by increasing heat deposition or 
cavitation [132-136]. 
 
2.5.3 Principles for Evaluating the Microvasculature with Contrast Agents  
Currently, there is much interest in the clinical application of ultrasound 
contrast agents, the use of which has the huge potential to expand the diagnostic 
capabilities of ultrasound investigations [137]. The characterization of these UCAs 
in terms of ultrasonic parameters, stability and bio distribution in the 
microvasculature is necessary prior to their clinical application. The detailed 
assessment of the microvasculature from correlation between the time-intensity 
curve and various experimental conditions necessitates the use of test flow 
phantoms suitable for the measurement of the flow parameters. Specifically, in the 
present study time-intensity curves were measured with three different types of 
flow phantoms. One is a single vessel flow phantom made of a single vessel, other is 
vascular flow phantom consisting of number of 15 vessels in a complex geometry 
and the last one is tumor vascular flow phantom in variety of vessel geometries such 
as curves, bifurcations, trifurcations, tumors, etc. 
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To effectively use contrast agents to quantify the microcirculation and 
extract useful information from a contrast time-intensity curve in any phantom 
model, an understanding of indicator dilution principles is required. Indicator 
dilution is based on applying a pharmacokinetic model to the test flow phantoms 
that accurately describes the transport of the tracer through the vasculature. 
The techniques and materials used for developing these flow phantoms must 
satisfy the fundamental assumptions of tracer studies [38]: 1. The amount of tracer 
injected does not change the physiology of the organism (does not disturb the 
system that is being measured); 2. The mass of the injected tracer is conserved; 3. 
The tracer is uniformly mixed in the carrier fluid; 4. The measured system is time 
invariant over the course of the study; 5. There is a known relationship between the 
signal that is measured and the tracer concentration. 
 
3.6 Flow Phantoms models 
The indicator-dilution theory is based on the law of mass conservation. After 
a dose of indicators is injected into the blood, the concentration of the agent is 
monitored as a function of time. The microbubbles are mixed in a few compartments 
in the circulatory system. Each of these compartments can be treated as a simple 
mixing chamber. A simple mathematical model can describe the mixing process 
inside the chamber and the response from each chamber can be characterized by a 
transfer function. Thus, by considering concentration of the indicator entering the 
mixing chamber as the input function, the output function defined as the 
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concentration leaving the chamber is simply the convolution of the input function 
and the transfer function [139]. With multiple mixing chambers in cascade 
connection, the same procedure can be repeated. The flow rate and the volume of 
the mixing chamber can then be derived if the transfer function of a particular 
mixing chamber can be estimated. 
Note that the concentration is not directly measured in practice. Instead, the 
backscattered acoustic intensity is used to represent the concentration of the 
microbubbles [140]. Such an approximation may not be valid when the bubble 
concentration is high [141] and [142]. Figure 8 is a schematic diagram of generation 
of the time-intensity curve. Assuming a transducer focuses a sound beam in a vessel, 
as shown in the left panel, the lower right panel shows a corresponding M-mode 
image with the horizontal axis denoting time and the vertical axis representing 
depth. At each time instance, intensities of the backscattered signals within the 
vessel are averaged and the average value becomes a point in the time-intensity 
curve shown in the upper right panel. This process continues at all times until a 
complete time-intensity curve is generated. 
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Figure 8: Illustrating Flow in Single Vessel Flow phantom 
 
3.6.1 Single-vessel flow phantom model: 
Consider the simple model depicted in Fig 9. Consider a system with a single 
inflow and a single outflow orifice. The internal structure of the system is of no 
concern for the present. Recirculation does not occur; that is, once a unit of fluid 
leaves the system it does not reenter. Blood flow of rate Q enters and leaves a blood-
mixing chamber of volume V via a single input vessel and a single output vessel.  
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Figure 9:  System with a single inflow and a single outflow orifice [145] 
When an indicator is injected suddenly into some portion of a vascular bed it does 
not all appear suddenly at a sampling site but it is dispersed with respect to time. 
The time required for a given indicator particle to flow from entrance to exit 
through the system, by whatever path, is its transit time. 
To illustrate this process, the following is considered: Let m1 units of 
indicator be injected at time zero into the entrance to the system, and measure the 
concentration of indicator at exit as a function of time, e (t). The amount of indicator, 
dm, leaving the system during a small time interval between time t and time t + dt is 
the concentration of indicator, c(t), multiplied by the volume of fluid leaving the 
system during this time interval, and this is the flow, Q, in units of volume/time, 
multiplied by the time interval, dt; that is, dm = c(t) Q dt. Because all indicator, m, 
must leave the system, equals the sum of the amounts leaving the system during all 
such time intervals, or 
    ∫            ∫     
 
 
   
 
 
  ………………(2.1) 
where 
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  ……………….(.22) 
Measuring the area under the observed indicator concentration-time curve and 
dividing it into the known quantity of injected indicator determine the unknown 
flow, Q, through the system. We now introduce the distribution, or frequency, 
function, h (t), which describes the fraction of injected indicator leaving the system 
per unit time at time, t; that is,  
      
       
  
  ……………(2.3) 
Where Q c (t) is the rate at which indicator leaves the system at time t.  
We must bear in mind that the area under a frequency function is unity and 
specifically 
∫      
 
 
      ∫       
  
   
  
  
  
 
 
    …………..(2.4) 
Combining equations (1) and (2), 
      
    
∫       
 
 
  …………..(2.5) 
Thus, to determine h(t) for fluid particles, each experimentally observed c(t) for 
indicator is divided by the area under the curve c(t) versus t. 
We can now determine the total volume of the system simply by adding together all 
the elements of volume in equation 2.5. Formally, we integrate equation 2.4 to find 
    ∫         
 
 
  ……….(2.6) 
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Because h(t) is the frequency function of transit times,  
       ∫         
 
  
 ……………(2.7) 
is by definition the mean of all transit times or the mean transit time, t. Therefore, 
       …………….(2.8) 
which states the fundamental fact that volume equals flow multiplied by mean 
transit time. In terms of the observed concentration of indicator, from equation (2.3) 
and equation (2.5), 
    
∫         
 
 
∫       
 
 
  ……………….(2.9) 
Where, the ratio of integrals is nothing more than instructions for finding t. 
 
Measurement of Flow and Volume by Constant Injection  
When indicator is introduced continuously into the entrance to the system at 
constant rate, mi, in units of mass per time, if mixing at inflow is complete, the 
concentration of indicator admitted to the system is 
  
 
 ………..(2.10) 
The system is unaware of whether the indicator diluter is using sudden or 
constant injection. In the illustrated case, no indicator appears at exit until the third 
time interval when the element of volume characterized by the briefest transit times 
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will display the first indicator particles. In this element of volume the concentration 
of indicator is mi/Q during the third time interval. The fraction of outflowing 
particles with this transit time is h(t) dt. Therefore, the concentration of indicator in 
the total outflow at this time is 
       
  
 
  …………(2.11) 
 
2.6.2 Multi-vessel Flow Model 
To understand the multi-vessel model we must look for a moment at a real 
system, say a vascular bed. In this case, we hypothesize the effects of not following 
of our first assumptions, or Real Vascular System. However, it is not even essential 
that all fluid pass through a single channel. If fluid from each input channel 
bifurcates into every other input channel before leaving the system, it may still be 
possible to measure flow [143]. The criterion for satisfactory intermingling is simply 
that, for the case of constant injection, the limiting concentration of indicator in 
every output channel must be the same. In a study, a linear systems theory approach 
was applied to flow measurement that treats the complex architecture of the 
microvasculature as a black box with a single input and single output [144]. 
However, the tracer injected into the flow system will dilute into the fluid volume 
and be carried along the different transit paths from the input to the output of the 
system. After a certain period of time, the tracer will begin to emerge at the output 
in proportion to the distribution of possible transit times. Provided that a flow 
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system is linear and stationary, conservation of mass requires that the mass of 
tracer that enters the system must be equaled by the sum of the mass that exits and 
remains in the system. 
 
Figure 10: Illustration of flow in a multi-vessel phantom [145] 
In practice, a known quantity of indicator is introduced into a fluid flowing at 
unknown rate through a system of unknown volume. Fluid is sampled or monitored 
at one or more points downstream from the plane of introduction and the 
concentration of indicator, diluted by the parent fluid, is measured as a function of 
time.  
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2.6.3 Tumor Vessel Flow Model: 
In this case, we hypothesize the effects of not following of our normal 
vascular assumptions, or real neoplastic system in a diseased condition. As cell 
growth continues, the microenvironment surrounding the tumor becomes critically 
hypoxic due to an exhaustion of local oxygen supply. This ‘stressed state’ stimulates 
a cascade of biological events that eventually form a dedicated tumor 
microvasculature (Fig. 11) [145]. In contrast to the self-limiting processes that occur 
during normal angiogenesis, tumor angiogenesis is wildly uncontrolled. However, it 
is not essential that all fluid pass through a single channel. Once a small avascular 
mass recruits a dedicated blood supply, a positive feedback loop is created driven by 
progressive tumor growth and a chronic state of hypoxia and acidosis [77, 145 and 
146]. Fluid from each input channel bifurcates into every other input channel, 
passes through leaky tumor vasculature and coalesces in the extravascular space 
before leaving the system. It may still be possible to measure flow. The criterion for 
satisfactory intermingling is simply that, for the case of constant injection, the 
limiting concentration of indicator in every output channel must be the same. 
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Figure 11: Illustration of Flow in tissue-mimicking tumor vasculature flow phantom  
[145] 
 
However, the tracer injected into the flow system will dilute into the fluid 
volume and be carried along the different tumorous transit paths from the input to 
the output of the system fig bb. Due to their size of several microns (pure 
intravascular contrast agents), contrast agents are able to enter the extravascular 
space of tumors and, thus, could theoretically be targeted against a larger number of 
disease specific markers beyond the targets expressed luminally on the vascular 
endothelial cells. Theoretically, tumor vasculature is thought to be leaky and 
defective, which will result in increased accumulation of tracer agents within the 
tumor [147, 148]. After a certain period of time, the tracer will begin to emerge at 
the output out of proportion to the distribution of possible transit times. Since a 
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flow system is non- linear, the mass of tracer that enters the system must not be 
equaled by the sum of the mass that exits and remains in the system. 
Also, early cancer detection and the imaging of tumor angiogenesis has been 
the most studied and promising target of ultrasound molecular imaging using 
microbubbles in cancer. The increasing interest in micro vascular imaging to study 
the blood flow has resulted in phantom development. Some phantoms have 
attempted to mimic a structural organ such as the prostate [149], while others have 
sought to mimic vasculature. Some vascular phantoms compatible with x-ray, 
ultrasound, and magnetic resonance were designed to mimic large vessels [150], 
such as the carotid artery [151]. Other studies have sought to create a vascular 
phantom using real vessels harvested from cadavers [152, 153]. Some of the major 
limitations of these designs are the size of the vessels and the absence of a leaky 
state, where small contrast agents may traverse between the mimicking vascular 
and tissue types. To the best of the knowledge, except for few commercially 
available; there is currently no phantom present within the literature that can 
provide information on tumor characteristics combined with the ability to measure 
flow at the micro vascular level. In this study we present three types of micro 
vascular phantoms (1) single vessel, (2) multi-vessel and (3) multi-vessel with 
artery bifurcations and structural abnormalities typical of diseased (tumor) 
vascular networks.  
Our motivations for developing such kinds of phantoms were both to develop 
vascular models with complex geometries to mimic diseased vasculature and also to 
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introduce flow to enable contrast enhanced ultrasound flow quantification. Some 
studies have indicated the ability to mimic a complex structure akin to that of 
vessels in tumors by intertwining silicone pipes in a water tank to some extent, 
allowing phantoms to be produced with ‘realistic’ flow and tumor properties but did 
not exhibit tissue-mimicking material for realistic ultrasound acoustic properties 
[154]. However, agar along with sephadex has been used to develop tumor and 
TMM for multi-modal imaging applications, the phantoms did not extract the 
representations of different types of vessels with flow characteristics. These two 
features have been published separately (154, 155). Phantoms that are used in 
medical imaging research to substitute for real vasculature can be modeled on 
anatomical features, such as vessels and vascular trees, including structures of 
diseased vasculature that behave inappropriately, such as a tumor tissue. In truth, 
tissue-mimicking materials (TMMs) have most commonly been made with an agar 
or gelatin base [156-162]. A major benefit the formation of wall-less vessels is a far 
more realistic approximation of in vivo acoustic properties.  Another benefit to 
modeling these features with wall-less agar vessels rather than using silicone tubing 
to mimic vessels is the phantom is reproducibility; the properties of the third 
phantom were more similar to those of the micro vascularization due to its 
dimensions while the parallelism with the capillaries reflect the complex and 
irregular structure of tumor micro vascularization with a known assumption for 
flow. The concept of wall-less vessels is explained in detailed in the next chapter of 
Materials & Methods. Once the phantoms are developed we further study, 
correlation between the time-intensity curves obtained under various flow 
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conditions. Additionally, the study was confirmed by the integration of ultrasound 
and CT scan images.  
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CHAPTER III 
MATERIALS & METHODS 
 
 
3.1 Preparation of Ultrasound Contrast Agents (UCAs) Microbubbles 
3.1. 1. Selection of Internal Gas: Octafluoropropane 
Octafluoropropane gases are widely used as the internal gas in the synthesis 
of ultrasound contrast agents because these gases are relatively inert, nontoxic and 
generally have low solubility in water [167]. Octafluoropropane also chemically 
known as Perflutren (Alpolo, FC-31-10, city, UK), in particular, was chosen for this in 
vitro study because it can be easily liquefied and handled in a simple laboratory 
routine due to its relatively high boiling temperature of -36.7°C [167].   
Octafluoropropane is chemically characterized as 1, 1, 1, 2, 2, 3, 3, 3-
octafluoropropane. It has a molecular weight of 188, empirical formula of C3F8 and 
has the following structural formula: The standard cylinder-valve outlet connections 
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of a Perflutren gas cylinder was made into a custom gas control manifold using   
 
 
 
 
 
 
Figure 12: Structural formula of Octafluoropropane [167] 
 
various metal and brass fitting to draw gas from the cylinder into 10 mL glass vial. 
The standard cylinder-valve outlet connections of a Perflutren gas cylinder was 
made into a custom gas control manifold using various metal and brass fitting to 
draw gas from the cylinder into 10 mL glass vial. 
 
3.1.2. Selection of Outer Lipid Shell 
1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1, 2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine (DPPE) 
a) DPPC has a molecular weight of 734, empirical formula of C40H80NO8P, and 
the following structural formula: 
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Figure 13: Structural formula of DPPC [167] 
b) DPPE has an approximate molecular weight of 5750 represented by empirical 
formula C265H527NO123PNa, and the following structural formula: 
 
Figure 14: Structural formula of DPPE [167] 
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Figure 15: Colored molecules are DPPC head group (shown in blue), DPPE head 
group (shown in green), and lipid tails (shown in gray), and water (shown in pink) 
[169, 170] 
 
The amount of lipid is a critical factor in the formation of shelled 
microbubbles. A comparative study of DPPE and DPPC shows that DPPE plays an 
important role in the membrane fusion mechanism and vesicle formation [169, 170] 
and DPPE molecules can form inter- and intra-molecular hydrogen bonds as shown 
in the above figure 15, where the amine group (hydrogen-donor) can interact 
strongly with water (hydrogen-acceptor). These strong intermolecular interactions 
affects membrane permeability, stability, and other biological properties normally 
associated with the functional operation of internal cell organelles. All these 
features make DPPC and DPPE very attractive in terms of membrane organization 
and functionalities—in particular, nonlinear behavior useful for contrast-enhanced 
ultrasound imaging. 
 
3.1.3 Preparation of Stock Solution 
The Stock solution was prepared by adding 10 mL of the Phosphate Buffer 
solution (PBS) (Sigma Aldrich, Saint Louis, MO, USA), 200mg of 1, 2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC) (Sigma Aldrich, Saint Louis, MO, USA), 50mg of 1, 
2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) (Sigma Aldrich, Saint 
Louis, MO, USA) and 1g of glucose (Sigma Aldrich, Saint Louis, MO, USA) in a beaker. 
The molar mass ratio of DPPC to DPPE was approximately 4:1. The mixture was 
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heated at 90 °C for 20-30 minutes in a boiling water bath to dissolve the DPPC and 
DPPE powders in glucose, pipette mixing every 5 minutes. After complete 
dissolution the solution was transferred to a 2 mL aluminum-sealed center rubber-
hole, glass bottle that can be stored at 4 degree Celsius up to 6 months.  
 
Figure 16: Preparation of Stock solution; The mixture with glucose, DPPE, DPPC 
and PBS in the mentioned ratio was heated at 90 °C for 20-30 minutes in a boiling 
water bath, then transferred to a 2 mL injection vials (aluminum-sealed rubber 
center glass bottles) 
 
250 μl of the prepared microbubble stock solution was transferred to an aluminum 
sealed 2 mL glass vial and incubated at 40°C for approximately 15 minutes. 50 μL of 
glycerol (Sigma Aldrich, Saint Louis, MO, USA) solution was added to this pre-
warmed solution. A manual cap crimping sealing machine was used to seal the 
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bottle by placing the crimping head above the aluminum cap and holding the 
crimping hand tight and pressing it. The pulling action while pressing the handle 
caused an airtight seal. Laboratory vacuum turret nozzle was connected to a hose. 
The distal end of the hose was furnished with connector to fit 2 mL needle. The air 
in the glass bottle is then replaced with vacuum as shown in figure 17.  
 
Figure 17: Customized technique to replace air with vacuum. Hose setting 
connected to a needle, which was injected into the glass bottle to replace air with 
vacuum 
 
Approximately 20 μL of Octafluoropropane gas was withdrawn from the cylinder by 
injecting a hypodermic needle through the vial aluminum- rubber cap, into the 
solution.  
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Figure 18: Customized setting of Octafluoropropane gas cylinder outlet to inject of 
Octafluoropropane gas into glass bottle through hypodermic needle 
 
The vial was shaken vigorously for 30 seconds at 4,300 rpm with amalgamator 
(Lantheus Medical Imaging Inc., MA, USA) at room temperature thus producing Gas-
filled lipid shell microbubble contrast agents as shown in figure 18. 
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Figure 19: Preparation of contrast Agent’s microbubbles: Stock solution in the glass 
bottle on the left side was amalgamated for 30 s to get gas-filled lipid shell 
microbubble contrast agents under the milky-white foamy layer in the glass bottle 
on the right side 
 
The synthesized UCAs were observed and analyzed by light microscope (Olympus, 
Hamburg, Germany) and a counting chamber (Invitrogen Countess, USA) to confirm 
bubble formation.  
 
3.1.4 Observation of Microbubbles under Microscope 
Microbubbles contrast agents were analyzed using high-end optical 
microscope under 40X magnification.  
3.1.5 Analysis of Microbubbles using Invitrogen Counting Chamber 
1 mL of UCAs was diluted in de-ionized water to make the suspension. 20 μL 
of cell suspension was transferred to a small micro tube having 20ul of 0.4% trypan 
blue stain. Trypan blue was added to estimate the number of active bubbles in the 
microbubble suspension. It was mixed gently by pipetting up and down. 20 μL of the 
sample mixture was added to the chamber ports on one side of the Countess™ cell 
counting chamber slide. The two chambers of the slide were labeled “A” and “B” for 
easy tracking of your samples. The Countess™ cell counting chamber slide was 
inserted, sample side ‘A’ first into the slide inlet on the instrument, making sure that 
the sample side A is inserted completely into the instrument. UCA microbubbles 
were counted and size distribution was studied. 
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3.2 Preparation of Tissue-mimicking vascular flow phantoms 
All phantoms were produced in three basic steps. First, a vascular mold was 
formed inside an acrylic box. Next molten agar was poured into the box and allowed 
to set. Finally internal mold materials were removed, resulting in a tissue mimicking 
material.  Details of individual phantom types are provided below. 
 
3.2.1 Single vessel flow Phantom 
A) Single vessel flow Phantom acrylic box construction 
Each phantom consisted of a 10 cm × 7 cm × 4 cm rectangular box of acrylic 
material as shown in figure 20. 11-mm-diameter cylindrical holes were made on the 
sides of the wall with the advanced laser-cutting machine. Holes were made to the 
correct diameter of 11 mm and depth 0.6 mm. A tap was used to cut threads inside 
the holes. It was held in line with the hole and turned clockwise to create threads 
and anti-clockwise to remove the thread bits. Pipe connectors (Cole–Parmer) of size 
1/8 x 1/8 NPT were glued in place with silicone adhesive (Huntsman Advanced 
Materials, Basel, and Switzerland). Reticulated foam (pore size 0.5- 1 mm) was glued 
with silicon adhesive to the inside wall and around the pipe connectors in the box. 
The reticulated foam provided a fixed structure into which the agar could flow when 
molten and, once set, prevented the agar gel from coming away from the connectors 
and the box when flow was applied. 
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Figure 20: Flow Phantom acrylic box construction of size 10 cm × 7 cm × 4 cm  
 
B) Preparation of Single vessel mold 
A wooden rod acted as mold for a single vessel, with diameters between 1 
and 2 mm, typical of rat femoral and common carotid arteries [171, 172]. The rod 
was inserted through both of the pipe connectors. The connectors were aligned to 
ensure that the rod was straight.  
 
C) Preparation of Tissue-mimicking mixture 
20 g or volume ratio 10% of Agar (Sigma Aldrich, Saint Louis, MO, USA) was 
added to 250 ml degassed, deionized and distilled water in a beaker. A magnetic 
stirrer was used while the mixture was heated in order to prevent the agar from 
burning at the bottom of beaker. Once the water bath heater had reached 90°C, 
continuous stirring was continued for 15 minutes in order for the mixture to reach 
equilibrium temperature. At the end of this period, the agar had dissolved and the 
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mixture appeared homogenous. After this, the heater was switched off, and the TMM 
was left to cool while still being stirred until the TMM temperature had reached 
50°C. 
The TMM was then poured into the phantom mold, covering the metal rod. 
The box was completely filled with TMM to form a relatively gas free upper 
phantom boundary allowing good coupling between the phantom and the imaging 
transducer. The TMM was left to set and after the agar was completely cured, the 
box was covered with a plastic sheet to prevent the TMM from drying out. 
The rod was carefully removed, and C-flex tubing (Cole–Parmer) was then attached 
to the external ends of the connectors to act as feed-in and feed-out pipes. The top 
and side views of the flow phantom prepared are shown in Figure 21. 
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Figure 21: Process of preparation of Single vessel flow phantom 
 
 
D) Single Vessel Flow Phantom Experimental Setup 
The single vessel phantom model was validated using a setup designed to 
provide stable and reproducible data under different flow conditions [93, 111]. The 
schematic diagram of the experimental set-up is illustrated in Figure 22.  
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The feed-in pipe of the tissue mimicking flow phantom was connected to a 
peristaltic pump (Watson Marlow, Falmouth, United Kingdom) generating a 
pulsatile flow with different flow rates. The reservoir containing 500 ml solution 
circulating in the closed system consisted of de-ionized water and UCA, which 
underwent constant stirring in the reservoir tank to obtain an even distribution of 
CA in the solution.  
The ultrasound linear probe (LG308-16A) was fixed by a tripod holder at 
longitudinal plane from the vessel phantom lumen. The transducer was fixed at a 
distance of 2 cm from the vessel lumen. 
 
Figure 22: Single Vessel Flow Phantom Experimental Setup 
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E) Data Acquisition 
After the peristaltic pump flow rate was set to a proper value and turned on, 
it was allowed to run degassed water for approximately 20 seconds before data 
acquisition so as to ensure the flow has been directed through the phantom and that 
a steady flow was developed. The pump was then turned off and the ultrasound 
probe (Fukuda Denshi, LG308-16A) was placed at a desired position and gently 
lowered to the surface of the phantom, taking care not to apply excess force and 
distort the TMM.  The cross-section of the single vessel (with diameter of 0.912mm) 
was imaged using B-mode imaging. The feed-in and feed-out pipes were placed in 
the reservoir.  A Fukuda Denshi Ultrasound scanner (Tokyo, Japan) was used to 
collect ultrasound data from the phantom. The imaging and experimental 
parameters are summarized in Table 3 and 4. The real-time videos were recorded to 
the PC through a Video Grabber card (Monoprice USB video & Audio Grabber, 
China) and saved for offline analysis. 
Mechanical Index 0.9 
Depth 2 cm 
Frame Rate 17 fps 
Probe Frequency 14 MHz 
Dynamic range 75 dB 
Flow-rate mL/min 10 – 50 mL/min 
 
Table I: The B-mode Ultrasound imaging parameters 
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Flow-rate mL/min Imaging Plane 
10 Longitudinal  
10 Lateral 
20 Longitudinal 
20 Lateral 
30 Longitudinal 
30 Lateral 
40 Longitudinal 
40 Lateral 
50 Longitudinal 
50 Lateral 
 
Table II: The B-mode ultrasound imaging experimental parameters 
 
3.2.2 Multi-vessel Flow phantom 
A) Multiple-vessel flow Phantom construction 
Figure 24 illustrates the phantom and measurement setup. A rectangular 
acrylic box of similar dimensions and tapping as used in single vessel phantom acted 
as the container for the multi-vessel phantom. Pipe connectors (Cole–Parmer) of 
size 1/8 x 1/8 NPT were glued in place with silicone adhesive (Huntsman Advanced 
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Materials, Basel, and Switzerland). Reticulated foam (pore size 0.5-1 mm) was glued 
with silicon adhesive to the inside wall and around the pipe connectors in the box. 
The reticulated foam provided a fixed structure into which the agar could flow when 
molten and, once set, prevented the agar gel from coming away from the connectors 
and the box when flow was applied.   
 
B) Preparation of Multiple-vessel mold 
Twenty consolidated processed wires of Cross sectional area of 0.3255 mm2 
acted as vessel mold for the multiple-vessel phantom, with diameter 0.6438 mm. 
The wires were inserted through both of the pipe connectors. The wires were folded 
into arched shape to mimic the shape of the typical capillary bed as shown in the 
following figure 23. 
 
Figure 23: The wires folded into arch shape to mimic the shape of the typical 
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capillary bed. Each wire is of diameter 0.6438 mm 
 
C) Preparation of Tissue-mimicking mixture 
20 g representing a 10% volume ratio of Agar was added to 250 ml degassed, 
deionized and distilled water in a beaker. The mixture was heated with the magnetic 
stirrer stirring inside to prevent the agar from burning at the bottom of beaker. 
Once the water bath heater had reached 90°C, the mixture was left to heat at this 
temperature under continuous stirring for 15 minutes. At the end of this period, the 
agar had dissolved and the mixture was homogenous. After this, the heater was 
switched off, and the TMM was left to cool while still being stirred until the TMM 
temperature had reached 50°C. 
The TMM was then poured into the phantom mold, covering the metal rod. 
The box was completely filled with TMM to form a strong upper vessel wall to allow 
the transducer to obtain images. The TMM was left to. After the agar was completely 
cured, the box was covered with a plastic sheet preventing the TMM from drying 
out. 
The wires were retracted from the box to form the hollow wall-less multiple 
vessels as shown in the figure, and C-flex tubing was attached to the external ends of 
the connectors to act as feed-in and feed-out pipes. The multi-vessel flow phantom 
prepared is shown in Figure 24. 
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D) Multiple- vessel Experimental Setup 
This section for multi-vessel phantom is similar to single-vessel phantom 
experimental set up. 
 
Figure 24: Multi-Vessel Flow Phantom Experimental Setup 
 
E) Data Acquisition 
During experiment, after the peristaltic pump flow rate was set to a proper 
value and turned on, it was allowed to run degassed water for around 20 second 
before acquiring actual data so as to ensure the flow has been directed through the 
flow phantom and a steady flow was developed. The pump was then turned off. 
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After this the ultrasound transducer probe was placed at a desired position and 
lowered as close as possible to the surface of the phantom without applying 
excessive pressure to the TMM.  The cross-section of the single vessel (with 
diameter of 0.912mm) was imaged using B-mode imaging. The feed-in and feed-out 
pipes were placed in the reservoir.  Once the set up was ready, A Fukuda Denshi 
Ultrasound scanner (Tokyo, Japan) equipped with linear probe (LG308-16A) was 
used to collect ultrasound data from the phantom.  The imaging and experimental 
parameters are summarized in Table 4. The real-time videos were recorded to the 
PC through a Video Grabber USB and saved for offline analysis. 
The cleaning procedure was performed after each experiment in order to remove all 
MBs in the closed system. During the cleaning procedure, the plastic tubes were 
flushed with de-ionized water. Cleaning procedures were performed every time 
before a new batch of CA was added to the system and a new data is collected. 
 
3.2.3 Tumor-vasculature flow phantom 
A) Tumor-vasculature flow Phantom construction 
Figure 24 shows the phantom and measurement setup. A rectangular acrylic 
box was used for other two types of vascular phantom acted as the container for the 
multi-vessel phantom.  
 
61 
 
B) Preparation of Neoplastic Vasculature mold 
The neoplastic vasculature was constructed to characterize the neoplastic 
blood flow properties with random tortuosity added to the wall-less vessels. 
Different vessel configurations were created. First, a single vessel representing 
“healthy” this develops tortuosity abnormalities along its centerline. This vessel 
network was designed to have two different bifurcations. At each bifurcation, the 
daughter vessel diverges in opposite directions. Prior to bifurcation, the daughter 
vessels resulting from that bifurcation trace equivalent paths to ensure smoothness 
at these junctions. By varying the angles at which daughter vessels diverge, we 
simulated vascular changes due to the onset of disease. The angles at which vessels 
diverge have been linked to the presence of liver disease [173], with the fibrous 
tissue in diseased livers causing wider divergence angles between hepatic vessels. A 
more tortuous vessel was further created by adding multiple independent vessels 
combined with the bifurcated vessels. This type of vasculature simulated 
morphological abnormalities relevant to tumor angiogenesis which mimic the onset 
of disease [174]. 
 
C) Preparation of Tissue-mimicking mixture 
20 g representing a 10% volume ratio of Agar was added to 250 ml degassed, 
deionized and distilled water in a beaker. The mixture was heated with the magnetic 
stirrer stirring inside to prevent the agar from burning at the bottom of beaker. 
Once the water bath heater had reached 90°C, the mixture was left to heat at this 
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temperature under continuous stirring for 15 minutes. At the end of this period, the 
agar had dissolved and the mixture was homogenous. After this, the heater was 
switched off, and the TMM was left to cool while still being stirred until the TMM 
temperature had reached 50°C. 
 
D) Preparation of Tumor mimicking material 
Mimicking of tumors requires the determination of an appropriate choice of 
tumor mimicking material in terms of increased complexity of vascular flow. Porous 
Polyurethane (PU) was selected due to its advantageous physical properties that are 
mainly open cell, permeable to air, breathable and water absorbent. Its most 
important attribute is, however, its elasticity; or, in other words, its reversible 
deformability - an attribute whose degree can be set during the production process 
according to its intended use as tumor mass of cells. The inclusions to mimic the 
cancer in different sizes were made using PU soft foam. The foam was modified as 
desired by cutting in a circular shape of approximate diameters of 10 mm, out of the 
foam sheet as shown in figure 25. In each tumor mold, a tiny hole for inserting the 
wires was drilled. These tumor mold inclusions were randomly inserted in certain 
regions on the wires. Such modifications served to alter the transmission pattern of 
ultrasonic waves for imaging in a manner different from the multi-vessel flow 
pattern and can be used to mimic the ultrasound characteristics of desired parts or 
conditions found in the diseased state of the human vasculature. 
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Figure 25: The foam was modified to a shape as shown in the figure by 
cutting in a circular shape of approximate diameter of 10 mm 
 
E) Preparation of Tumor vasculature flow phantom 
The PU tumor inclusions were inserted through the bifurcated and 
independent wires and placed within the box. The TMM was poured into the 
phantom mold, covering the tumor inclusions and the wires. The box was 
completely filled with TMM to form a strong upper vessel wall to allow the 
transducer to obtain images. The TMM was left to set. After the agar was completely 
cured, the box was covered with a plastic sheet preventing the TMM from drying 
out. Inclusions that mimic the properties of tumors were hence looked like strung 
onto different vessels placed into the phantom container at specific locations and 
were embedded in TMMs. The wires were retracted from the box to form the hollow 
wall-less multiple vessels as shown in the figure while the tumors remained 
embedded in the TMM. C-flex tubing (Cole–Parmer) was attached to the external 
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ends of the connectors to act as feed-in and feed-out pipes. The side and top views of 
the tumor vessel flow phantom in a 3D solid work design are shown in Figure 26. 
 
Figure 26: Tumor vessel flow phantom in a 3D solid work design: The upper 
phantom is the side view and lower phantom is the top view of the tumor vessel 
flow phantom in a 3D solid work design showing consolidated wires and tumors 
embedded in agar TMM to simulate the morphological abnormalities relevant to 
tumor angiogenesis which mimic the onset of disease. The wires are then retracted 
and tumors are left with wall-less vessels embedded in the agar tissue 
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F) Tumor vasculature experimental set up 
This section is similar to multi-vessel flow phantom experimental set up. 
 
Figure 27: Tumor vasculature Flow phantom experimental set up 
 
G) Data Acquisition 
This phantom represented simulations of a healthy vessel, which has 
developed high spatial-frequency tortuosity abnormalities, which are typical of 
cancerous vasculature. During experiment, the peristaltic pump flow rate was set to 
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a given value and then turned on. It was allowed to run degassed water for around 
20 second before acquiring actual data so as to ensure the flow has been directed 
through the flow phantom and a steady flow was developed. The pump was then 
turned off. After this the ultrasound transducer probe was placed at a desired 
position and lowered as close as possible to the surface of the phantom without too 
much pressing into the TMM.  The cross-section of the single vessel (with diameter 
of 0.912mm) was imaged using B-mode imaging. The feed-in and feed-out pipes 
were placed in the reservoir.  Once the set up was ready, a Fukuda Denshi 
Ultrasound scanner (Tokyo, Japan) equipped with linear probe (LG308-16A) was 
used to collect ultrasound data from the phantom. The real-time videos were 
recorded to the PC through a Video Grabber USB and saved for offline analysis. 
A cleaning procedure was performed after each experiment in order to remove all 
MBs in the closed system. During the cleaning procedure, the plastic tubes were 
washed with de-ionized water. Cleaning procedures were performed every time 
before a new batch of CA was added to the system and a new data is collected. 
 
3.3 Computed Tomography (CT): Comparative study of Vessel diameter 
measurement   
To verify ultrasound-derived vessel diameter measurements, multi-detector 
CT was also used to image the agar-based wall-less single-vessel, multi-vessel, and 
tumor vessel flow phantoms. In this experiment, the ultrasound experimental set up 
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used to evaluate flow parameters was not implemented, instead only the individual 
phantoms were scanned without any flow of contrast microbubbles within the flow 
phantoms.  
Imaging data were acquired using a 16-slice CT system (Philips, Brilliance 
Big Bore, USA) which has a spatial resolution of 16 lp/cm in the x-, y-, and z-axes.  
The Brilliance CT Big Bore Radiology technology configuration, which incorporates 
the 85 cm large, bore and 60 cm true scan field-of-view. The flow phantom was 
placed in the iso-center of the scanner. Data were acquired by using a RapidView 4D 
reconstruction CT diagnostic protocol. Parameters included a 60 cm true scan field 
of view, 300 effective mAs (effective tube current–time product is tube current–time 
product divided by pitch), detector collimation of 2 x 0.6 mm, 16 x 0.75 mm, 16 x 1.5 
mm, 8 x 3.0 mm, 4 x 4.5 mm, and a gantry rotation time of 0.44 second. CT images, 
which were reconstructed using extended display field of view technology with 
image matrix 512x512 which offered extrapolated reconstruction for visualization 
of anatomy out to 70 cm, which may be useful in radiation oncology for avoidance in 
treatment planning. Due to reconstructive distortion data outside of 60 cm was not 
considered to be of diagnostic quality and thus omitted. With this process, 15 static 
images of the phantoms were created at each scan level.
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CHAPTER IV 
RESULTS & DISCUSSION 
 
 
4.1 RESULTS 
4.1.1 Ultrasound Contrast agents: 
Prior to application, the microbubble solution obtained by amalgamation of the 
sealed vial was allowed to settle down for approximately 2 minutes. 1.5 mL of 
contrast agent was withdrawn from beneath the foamy surface as shown in the 
figure 19. The fluid below the foam layer was used as the US contrast agent.  In an 
initial assessment, the synthesized UCAs were analyzed by using high-resolution 
optical microscopy to confirm bubble formation.  The diameter of the microbubbles 
was measured under a high-end optical microscope and ranged from 5 to 20 
μm. Figure 1 shows a microscopic image of prepared lipid-based contrast agent. It is 
noted that the bubbles may appear to be artificially large in the image because they 
were compressed when taking the picture. A cell counter and plotted against 
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number of microbubbles as shown in figure 2 measured the size distribution of the 
contrast agent. The median diameter was 18 μm and the minimum size of the 
microbubble was 5 μm.  
 
 
 
 
 
 
 
 
Figure 28: Two-dimensional microscopic photo of the UCAs. The shape of the UCAs 
was observed under optical microscope at 40X magnification. 
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Figure 29: Size distributions of UCAs. The size distribution of UCAs was measured 
with a cell counter and plotted against number of microbubbles. 
 
 
 
 
  
 
 
 
Figure 30: Study of the microbubble size on a cell counter. 
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4.1.2 Detection by Ultrasound 
During preliminary examinations with microbubble contrast, individual 
“dots” of ultrasound reflection can be visualized. To confirm whether these signals 
represent individual microbubbles, very dilute suspensions of ultrasound contrast 
agents or individual microbubbles were prepared and studied by ultrasound 
imaging. Ultrasound of dilute microbubble dispersions (free floating) demonstrated 
distinct white foci; concentration of these sites was consistent with signals from 
individual microbubbles over a period of time. The characteristic diffusion of UCA 
under ultrasound can be seen in Figure 31. The stability of the synthesized UCAs 
was measured by ultrasound imaging over a 2 hours period. The characteristics of 
each UCA microbubbles under ultrasound can be seen in Figure 7. As expected, the 
presence of a small amount of UCA increases the reflection so that the average 
brightness on ultrasound imaging. It was seen that very dilute dispersions of 
microbubbles do present, as individual white dots of ultrasound scatterers that 
were consistent with the ultrasound imaging were individual microbubbles. 
Additionally, the average brightness decreases exponentially with time due to the 
breakdown of microbubbles in the degassed water. The main reason for the 
different maximum brightness may be the relatively small density of microbubbles 
in the degassed water. 
As UCAs microbubbles are generally not intended to be used after a long 
period of time, the long-term stability of the agent was evaluated to verify the 
imaging capabilities of the synthesized UCAs. Figure 31 shows the durability of the 
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average brightness over time (0, 1, 3, 5, 7, 9 min, 1 hr. and 2hrs) after the injection of 
the UCA microbubbles via hypodermic needle as shown in figure. The echogenicity 
of microbubbles shell show significant reductions after 2 hours, suggesting that they 
should be used in experiments on the day of amalgamation within 1 hour of 
synthesis (see Figures 7 and 8).  
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Figure 31: The characteristic diffusion of UCA microbubbles by ultrasound in 
degassed water 
 
 
4.1.3 Flow phantom experiments 
Three different flow phantoms were tested. B- Mode ultrasound acquisitions 
were obtained in two imaging planes as shown in table 4 and 5 of Materials & 
Methods section. With every bolus injections and five different flow-rates, around 
70 real-time B-mode ultrasound video clips were recorded and stored for off-line 
analysis. As the contrast agent is entering the phantom, the concentration of the 
microbubbles is plotted as a function of time. At each time instance, intensities of 
the backscattered signals from the microbubbles within the vessel are averaged and 
the average value becomes a point in the time-intensity curve shown in the upper 
right panel. This process continues at all times until a complete time-intensity curve 
is generated. For the off-line analysis of the B-mode data, the intensities from the 
manually chosen regions-of-interest (ROI) were measured. Because of the stable 
experimental setting, the ROI we chose was on the similar positions during all 
different flow rates for single-vessel phantoms. While different ROIs were chosen 
for multi-vessel and tumor vessel phantoms depending on the proper visualization 
of multiple vessels and tumor arteries in the phantoms respectively. Time-intensity 
curves figure 32 (b) was generated for all three types of phantom real-time video 
clips in ROIs as shown if figure 32 (a). 
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The curve can be divided into three regions. The first region on the curve 
shows the intensity plateau of approximately 10 s and it corresponds to a case 
where there are no microbubbles, usually before the injection of contrast 
microbubbles. The second region is from 10 s to 30 s and it relates to injection of 
contrast with a complete mixing and dilution of microbubbles. Here, the time-
intensity curve increases to the maximum due to the wash-in of the contrast 
followed by a third region which relates to the decrease of the curve due to the 
gradual wash-out of the contrast.  
 
Figure 32 (a): ROIs drawn from still B-mode images of a single-vessel flow 
phantom 
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Figure 32 (b): Time intensity curve extracted from ROIs 
 
To achieve more quantitative description of the curve shape, three 
parameters were studied which are of critical interest for all application areas.  
Peak of Enhancement (PE): It is the time when contrast enters the ROI and the 
signal intensity rises above the baseline intensity (Ibase).  
Initial time of Enhancement (ET): This is the time of steepest slope representing 
the highest enhancement rate during the contrast wash-in. It is mainly characterized 
by tissue vascularization.  
Time to Peak (TTP): It is the point in time where the contrast washes in and the 
signal enhancement actually starts till it reaches the first peak of intensity. 
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Tmax: the volume of the interstitial space the time period between the first peak of 
intensity and the maximum enhancement mainly characterizes it. 
Washout rate: It is the point of time where the curve gradually starts to decrease. 
After this diffusion rate of microbubbles drops completely. 
  The time-intensity curves were further analyzed in MATLAB to calculate the 
slope. This parameter refers to the Up-slope of the signal-intensity curve during the 
early phase of contrast enhancement as shown in figure 32 (b). The curve region is 
considered crucial for the actual quantification of the flow. Three points on the 
curve selected are averaged and the resulting slope is calculated as shown in figure 
33.  
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Figure 33: Calculation of slope in the region of initial time of enhancement (ET) 
 
4.1.3.1 Single Vessel Flow Phantom: 
The plots of time intensity curves for ROI imaged according to the 
parameters discussed in table 4 are shown in appendix section. The intercepts on 
the curve close to the first peak intensity regions are not considered.  The product of 
the flow rate and the slope corresponds to the volume of a single vessel flow 
phantom. The results are shown in the last column with an average of 23.84 mL. 
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Table III: Summary of the derived slopes of the time-intensity curves with different 
flow-rates and imaging planes within a single-vessel flow phantom is shown below 
Flow Rate 
(FR) (mL/min) 
Probe 
Position 
Slope (s) 
S1     S2     S3 
Average 
Slope 
(s) 
Mean 
Slope 
 
(s) 
10 Longitudinal 0.59  0.6  0.51 0.56  
10 Lateral 0.45 0.45 0.505 
20 Longitudinal 0.34  0.5  0.54 0.46  
20 Lateral 0.64 0.64 0.550 
30 Longitudinal 0.64  0.65  0.52 0.60  
30 Lateral 0.77 0.77 0.705 
40 Longitudinal 0.90 0.82  0.85 0.85  
40 Lateral 0.61 0.61 0.730 
50 Longitudinal 0.96 0.77  0.92 0.88  
50 Lateral 1.09 1.09 0.985 
 
The slopes associated with the single-vessel phantom are plotted as a 
function of the flow rate is shown in figure 34. The slopes were derived from least-
square fitted exponential time-intensity curves based on the imaging 
measurements. The correlation coefficient between the mean slope measurements 
and the least squares fitted line is all higher than 0.95, indicating a good linear 
relationship between the mean slope and the flow-rates. For all data, the mean 
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proportional difference of the slope measurements and flow-rate was +0.695 ± 0.18 
(mean ± SD). 
 
Figure 34: Scatter diagram shows correlation between flow-rate measurements 
and mean slope measurements at 5 different flow-rates in two imaging planes  (n= 
5). Regression analysis showed good linear correlation between mean slope 
measurements and flow-rates (r= .95, y= 0.0114x + 0.353). 
 
 
4.1.3.2 Multi-Vessel Flow Phantom: 
The multi-vessel flow phantom was validated using an experimental set up as 
discussed in the method section and parameters shown in table 4. Time-intensity 
curves figures 32 (a and b) were generated for multi-vessel phantom in ROIs as 
shown if figure 32 (a). The plots of time intensity curves for ROI imaged according to 
y = 0.0114x + 0.353 
R² = 0.91168 
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the parameters discussed in table 4 are shown in appendix section. The intercepts 
on the curve close to the first peak intensity regions are not considered.  
Table IV: Summary of the derived slopes of the time-intensity curves with different 
flow-rates and imaging planes within a single-vessel flow phantom 
Flow Rate 
(FR) 
mL/min 
Imaging  
plane 
Slope (s) 
S1      S2    S3      S4 
Average 
Slope 
(s) 
Mean 
Slope 
(s) 
10 Longitudinal 0.3  0.15  0.16  0.15 0.19  
10 Lateral 0.29  0.19  0.25  0.41 0.28 0.235 
20 Longitudinal 0.17  1.10  1.00 0.64 0.36  
20 Lateral 1.08  0.51  0.46  0.14 0.36 0.36 
30 Longitudinal 0.44  0.53  0.28  0.47 0.43  
30 Lateral 0.21  0.09  0.17  0.18 0.16 0.295 
40 Longitudinal 0.57  0.19  0.37  0.46 0.41  
40 Lateral 0.45  0.39  0.39  0.38 0.40 0.405 
50 Longitudinal 0.44  0.40  0.31  0.28 0.73  
50 Lateral 0.51  0.42  0.25  0.28 0.55 0.64 
     
 
The calculated values of early slope associated with the time-intensity curves 
within the multi-vessel phantom are plotted as a function of the flow rate is shown 
in figure 35. The slope values were derived from least-square fitted exponential 
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time-intensity curves based on the selected ROIs. The correlation coefficient 
between the mean slope measurements and the least squares fitted line is 0.86, 
indicating a good correlation between the mean slope and the flow-rates. 
For all data, the mean proportional difference of the slope measurements and 
flow-rate was + 0.387 ± 0.15 (mean ± SD). 
 
 
Figure 35: Scatter diagram shows correlation between flow-rate measurements 
and mean slope measurements at 5 different flow-rates in two imaging planes  (n= 
5). Regression analysis showed good linear correlation between mean slope 
measurements and flow-rates (r= .86, y= 0.0086x + 0.1305). 
 
 
y = 0.0086x + 0.1305 
R² = 0.7565 
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4.2.2.1 Slopes vs. Flow-rate for Single vessel and multi-vessel flow phantoms 
The correlation coefficient between the mean slope measurements and the least 
squares fitted line is 0.90, indicating a good linear correlation between the single-
vessel and Multi-vessel flow phantoms.  
 
Figure 36: Mean slope measurements derived from Time intensity curves of single-
vessel and Multi-vessel in two imaging planes at 5 different flow-rates. (n=5, mean ± 
SD, were P≤0.05)  
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4.1.4 Measurement of Intensity (Maximum Intensity, Imax) at Different flow-
rates 
Table V: The maximum intensity vs. Flow-rates in single vessel Phantom.  
Flow rate 
mL/min 
Imaging 
Plane 
Maximum Intensity 
Imax (AUC) 
Mean Intensity 
AUC 
10 Longitudinal 38  
33.5 10 Lateral 29 
20 Longitudinal 22.5  
24.75 20 Lateral 27 
30 Longitudinal 38.5  
30.25 30 Lateral 22 
40 Longitudinal 34  
24.5 40 Lateral 15 
50 Longitudinal 36  
27 50 Lateral 18 
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Figure 37: Maximum intensity vs. Flow-rates in single vessel Phantom. Regression 
analysis showed good linear correlation between mean slope measurements and 
flow-rates (r= .52, A= 31.733, β =0.004) while r=0.52 and P=0.79 
 
The table 8 The signal intensity versus pulsing interval plots were fitted to an 
exponential function y=A(1−e−βt), where A is the plateau video intensity reflecting 
the micro vascular cross-sectional area, and β reflects the rate of rise of signal 
intensity and, hence, microbubble velocity. To normalize intensity values they were 
subjected to linear regression analysis. Closer correlations were found between 
flow-rates and the signal intensity values with r=0.52 and P≥0.05. 
After 10   2 s, the individual time-intensity curves in figure 37 with different 
flow-rates showed an increase of the signal intensity to a maximum, followed by a 
decrease of the curve, due to wash-out of the contrast. Along with the increase in the 
y = 31.733e-0.004x 
R² = 0.2699 
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flow-rate, there was an increase of the signal intensity. Further increase of the flow-
rate did not lead to any increase in the peak signal intensity.  
Table VI: The maximum intensity vs. Flow-rates in a multi-vessel Phantom 
Flow rate  
mL/min 
Imaging 
Plane 
Mean Intensity 
Imax (AUC) 
Average 
Intensity 
AUC 
10 Longitudinal 21  
23 10 Lateral 25 
20 Longitudinal 24  
36 20 Lateral 28 
30 Longitudinal 34  
31 30 Lateral 17 
40 Longitudinal 26  
21.5 40 Lateral 22.5 
50 Longitudinal 19.8  
18.5 50 Lateral 16.5 
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Figure 38: Maximum intensity vs. Flow-rates in Multi-vessel Phantom. Regression 
analysis showed good linear correlation between mean slope measurements and 
flow-rates (r= .52, A= 33.55, β =0.01) while r=-0.51 and P=0.62 
 
 
4.1.5 Ultrasound based velocity measurements 
For flow velocity estimation, the single-vessel phantom experimental setup 
as shown in Figure 3 and 4 were considered. The video clips of the microbubbles 
injection recorded for the first experiment were analyzed in MATLAB to obtain the 
time constant (t) of the fluid microbubbles flowing at different flow-rates specific 
velocity. To calculate time (t), two ROIs were selected. First region corresponds to 
the time of initial time of enhancement of the microbubble wash-in and the second 
region relates to the time curve gradually started to descend to baseline due to 
microbubble washout. To estimate the time-delay, two points T1 and T2 were 
y = 33.55e-0.01x 
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selected on the curve, which displayed time delay between the times of initial 
enhancement of the microbubble for both the ROIs. By subtracting T1 from T2, time-
delay was calculated as (t). This was repeated for images at different flow-rates 10, 
20, 30, 40 and 50 mL/min. For distance calculation, the actual physical distance 
between the two ROIs was measured to estimate the distance as shown in the figure. 
The ultrasound based velocity measurements from the time-intensity curves across 
a longitudinal view of ROIs of the vessel in the flow phantom at flow rates of 10, 20, 
30, 40 and 50 mL/min various parameters were measured.  
Table VII: The summary of the ultrasound based velocity measurements 
derived from the distance between the two ROIs and the time difference (T2-T1) 
between the times of delay of initial time of enhancement on the time-intensity 
curves with different in a longitudinal view within a single-vessel flow phantom. 
 
Flow rate 
mL/ min 
Distance 
(mm) 
Time  
(t) (sec) 
Flow Velocity 
(mm/s) 
10 5.8 5 1.16 
20 5.83 6 0.96 
30 5.24 2 2.62 
40 6 5 1.20 
50 6.02 3 2 
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The velocity profile obtained from a phantom is shown in the figure. The peak 
velocity was located at the center of the vessel, decreasing to a minimum at the 
vessel walls. There was an increase of the velocity along with the increase in the 
flow-rate. Further increase of the flow-rate did not lead to any increase in the 
velocity. 
 
Figure 39: Ultrasound based velocity measurements vs. Flow-rate in Single-vessel 
Phantom. Regression analysis showed no statistical difference between the flow 
velocity measurements and flow-rates (y= .0192x + 1.012) while correlation 
coefficient =0.65 and P≤0.05 
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Figure 40: When performed in conjunction with a mammogram, the SonoCiné 
ultrasound can reveal cancers that may otherwise be missed 
 
 
4.1.6 Tumor vasculature flow phantoms: 
Figure 40 shows invasive breast cancer scanned with contrast-enhanced 
ultrasound imaging, which was not visible to either a mammogram or sonogram. 
Mammography finds most breast cancers, but in some subset of women who have 
dense breasts, it only finds about half of the cancers. Contrast-enhanced Ultrasound 
has been a very good tool at seeing cancers when you know where they are, but it 
had not been used for finding breast cancers in normal breasts. 
Enhancement refers to a process by which lesions revealed on an ultrasound 
image increases in contrast at a specific rate over a given short-time interval, which 
indicates increased vascularity to the area. A neoplasm will tend to have an 
increased vascularity when compared to normal breast tissue. However, contrast 
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enhancement is not specific to malignant tumor. Many benign breast tissues can 
exhibit variable degrees of contrast enhancement as well. Contrast 
enhancement associated with cancerous tissue is differentiated from benign-type 
enhancement through the use of Dynamic contrast-enhanced ultrasound technique.  
The ultrasonography was initially performed in B mode to identify the focal 
lesion.  The area to be imaged was identified before the injection according to 3 
rules: (1) the whole tumor should be seen on the image, if possible; (2) the sectional 
plane should contain the solid part (wall, septa, and papillae) of the tumor; and (3) 
the most vascularized area should be selected by ultrasound imaging. Then a dose of 
1mL contrast microbubbles diluted in 500 mL degassed water was injected as a 
rapid bolus through the phantom. This was not followed by saline flush. The first set 
of experiments was performed on tumor region 1, to study the relationship between 
in-flow and out-flow vs. flow rates. The fluid mixture in the phantom was allowed to 
flow in the tumor to measure the in-flow. The in-flow was measured in longitudinal 
direction, at five flow-rates 10, 20, 30, 40 and 50 mL/min. Now the orientation of 
the probe was changed to lateral direction. The fluid mixture in the phantom was 
now allowed to flow out of the tumor to measure the out-flow. The out-flow was 
also measured in two directions, longitudinal and lateral at five flow-rates 10, 20, 
30, 40 and 50 mL/min as shown in table xx.  The same set up was maintained for 
two more set of experiments that were performed on tumor region 2 and tumor 
region 3 as shown table 5. The sequence of recording the raw data of the contrast in-
flow and out-flow lasted at least 15 seconds or until the uptake disappeared 
completely when the pump was turned off.  
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Theoretically, cancerous tissue will show a more than 70% increase in signal 
intensity over baseline also known as initial enhancement curve, within the first 60-
90 seconds because of large vessels in the tumor. This marked increase in signal 
intensity is followed by a wash out phase, which is the result of increased vascular 
permeability. On a time vs. signal-intensity curve, the percentage of maximal signal 
increase will tend to correlate very well to the density of the micro-vessel count. It is 
more common to encounter a higher ratio of micro-vessels in the tumor periphery 
rather than in the tumor center when the tumor is malignant and not benign. Hence, 
as a part of preliminary study of the tumor vessel phantoms, we chose to analyze the 
in-flow and out-flow occurring at the tumor periphery under five different flow-
rates. 
The region with the greatest vascularization density was targeted as the ROI 
as shown in the figure. The signal intensity vs. time of the contrast in-flow and out-
flow to the tumor was plotted graphically in both longitudinal and lateral imaging 
planes. 
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Tumor 1 
Table VIII: Summary of Results obtained from the experimental parameters as 
discussed in table 5 is shown in the table 
Flow Rate 
(FR) 
mL/min 
Imaging 
Plane 
Inflow 
(mL) 
Average 
In-flow 
(mL) 
Outflow 
mL 
Average 
Out-flow 
(mL) 
10 Longitudinal 0.03  0.14  
10 Lateral 0.03 0.03 0.51 0.32 
20 Longitudinal 0.06  0.46  
20 Lateral 0.03 0.04 0.57 0.51 
30 Longitudinal 0.02  0.07  
30 Lateral 0.22 0.12 0.5 0.15 
40 Longitudinal 0.01  0.19  
40 Lateral 0.01 0.01 0.09 0.34 
50 Longitudinal 0.11  0.08  
50 Lateral 0.01 0.06 0.75 0.12 
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Figure 41: Up-slope values of in-flow vs. flow-rate in tumor region 1 
 
 
Figure 42: Up-slope values of out-flow vs. flow-rate in tumor region 1 
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Figure 43: Up-slope values of in-flow and out-flow vs. flow-rate in tumor region 1 
 
The parameters obtained from tumor region 1 after contrast injection showed 
almost same arrival time and the signal intensities showed an undefined pattern. 
The results were consistent for the other tumor regions (2 and 3) also.  
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Tumor 2 
The region with the greatest vascularization density in second tumor region, 
was targeted as the ROI as similar to tumor region 1. The signal intensity vs. time of 
the contrast in-flow and out-flow to the tumor was plotted graphically in both 
longitudinal and lateral imaging planes. 
Table IX: Results obtained from the parameters discussed in table 5 are shown in 
the table for tumor region 2 
Flow Rate 
(FR) 
Probe 
Position 
Inflow 
 
Average 
In-flow 
Outflow Average 
Out-
flow 
10 Longitudinal 0.52  0.14  
10 Lateral 0.05 0.28 0.51 0.32 
20 Longitudinal 0.25  0.46  
20 Lateral 0.7 0.47 0.57 0.51 
30 Longitudinal 0.01  0.07  
30 Lateral 0.08 0.04 0.5 0.28 
40 Longitudinal 0.05  0.19  
40 Lateral 0.64 0.34 0.09 0.14 
50 Longitudinal 1.13  0.08  
50 Lateral 0.12 0.62 0.75 0.41 
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Tumor 3 
The region with the greatest vascularization density in second tumor region, 
was targeted as the ROI as similar to tumor region 1. The signal intensity vs. time of 
the contrast in-flow and out-flow to the tumor was plotted graphically in both 
longitudinal and lateral imaging planes. 
Table X: Summary of Results obtained from the experimental parameters as 
discussed in table 5 for tumor region 3 
Flow Rate 
(FR) (mL/min) 
Imaging 
Plane 
Inflow 
(mL) 
Average 
In-
flow(mL) 
Outflow Average 
Out-
flow(mL) 
10 Longitudinal 0.03  0.06  
10 Lateral 0.09 0.06 0.13 0.09 
20 Longitudinal 0.06  0.19  
20 Lateral 0.09 0.07 0.08 0.13 
30 Longitudinal 0.15  0.08  
30 Lateral 0.18 0.16 0.06 0.07 
40 Longitudinal 0.14  0.13  
40 Lateral 0.06 0.10 0.08 0.10 
50 Longitudinal 0.06  0.88  
50 Lateral 0.08 0.07 0.15 1.03 
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4.1.7 Computed Tomography (CT): Comparative study of Vessel diameter 
measurement   
4.1.7.1 Data Analysis 
The standard deviation of relative diameters was calculated from CT data 
and ultrasound images for visible vessels in each phantom. The differences in 
relative diameter changes between CT and ultrasound measurements were first 
computed. Relative diameter changes in millimeters were calculated as  
[(DUltrasound  (std) – DCT)/DCT]  
(Where DUltrasound is maximum diameter of US measurements and DCT is relative 
diameter of CT scan measurements) from the CT data, were compared with the 
measurements obtained with the ultrasound reference standard diameter as shown 
in figure.  
 
The minimum and maximum ultrasound diameter measurements ranged 
from 0.03 to 1.09 mm of the vessels in three types of phantoms as shown in figure 
(44 to 51), whereas the corresponding minimum and maximum CT diameter 
measurements ranged from 0.93 to 4.49 mm. Compared to ultrasound reference 
standard measurement 0.04 mm, the CT diameter measurements for single-vessel 
diameter changes ranged from 0.93 to 2.73 mm, multi-vessel diameter changes 
ranged from 1.43 to 2.08 mm and tumor-vessel diameter changes ranged from 0.93 
to 2.73 mm, with overall standard deviation of SD = 0.123. 
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Table XI: Summary of standard deviation of Relative Diameter Measurements with 
Difference in Relative Diameter Change between Optical and CT Measurements 
Phantoms Ultrasound 
(mm) 
D1 
CT scan (mm) Relative 
Diameter change 
CT (mm)  D2 
Relative 
diameter 
change (mm) 
Std min max (Min-max)/min D1-D2/D1 
Single-vessel 
1 
0.04 0.93 2.53 0.63 0.93 
Single-vessel 
2 
0.04 1.18 2.73 0.45 0.911 
Multi-vessel 
1 
0.03 1.43 2.61 0.45 0.93 
Multi-vessel 
2 
0.04 1.21 3.08 0.60 0.93 
Tumor-
vessel 
1.09 1.49 4.49 0.66 0.65 
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Sample Standard Deviation, s 0.12337017467767 
Variance (Sample Standard), s2 0.0152202 
Population Standard Deviation, σ 0.11034563879012 
Variance (Population Standard), σ2 0.01217616 
Total Numbers, N 5 
Sum: 4.351 
Mean (Average): 0.8702 
 
 
 
 
Figure 44: CT image of Single-vessel diameter measurement in phantom 1 
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Figure 45: CT image of Single-vessel diameter measurement in phantom 2 
 
Figure 46: CT image of multi-vessel diameter measurement in phantom 1 
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Figure 47: CT image of multi-vessel diameter measurement in phantom 2 
 
Figure 48: CT image of tumor-vessel diameter measurement in tumor-vessel 
phantom 
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Figure 49: US image of Single-vessel diameter measurement in phantom 1 and 2 
 
 
Figure 50: US image of Multi-vessel diameter measurement in phantom 1 and 2 
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Figure 51: US image of tumor-vessel diameter measurement in tumor-vessel 
phantom 
 
 
4.2 Discussion 
Currently, the most popular microbubble shell design for a blood pool 
contrast agent is one clinically approved and prepared based on lipid shell design. 
The sole protein-based approved agent Optison/FS069, with the formal generic 
name ‘‘Perflutren protein microspheres’’, contains human albumin shell and 
perfluoropropane core. Preparation of these microbubble agents is often achieved 
by high shear gas dispersion in the aqueous mixtures. In case of one of the contrast 
bubble materials, Definity and MRX-115 (perflutren lipid microspheres), aqueous 
phase with lipid mixture is packaged in a vial with perfluoropropane gas headspace, 
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stopper sealed and stored in the refrigerator. The sealed vial is subjected to high-
speed shaking for 45 s for microbubble generation immediately. General design of 
the microbubble contrast agent is simple: a gas core that is surrounded by a 
stabilizer shell, with the whole structure dispersed in an aqueous medium 
(degassed water) and injected into the phantoms. Microbubble contrast agents, in 
the form of intravenous injectable, are now routinely used as markers of blood flow. 
During initial work in the creation of UCA microbubbles, it was determined through 
analysis with both optical microscopy and a cell counter that dilution rates need to 
be controlled according to the density of microbubbles.  In this study the dilution 
rate of microbubbles was set to a constant concentration of 1 mL: 500 mL water.  
Also, during initial work in the imaging of UCA microbubbles with 
ultrasound, it was determined that the microbubbles were not completely mixed 
when the constant flow was used. Thus, the absolute flow quantification is not 
accurate unless the effective mixing volume can be found.  The differences in 
characteristics of the time-intensity curves obtained based on the concentration of 
microbubbles, may require different signal-processing techniques for the mixing of 
microbubbles in the two types of phantoms. The derived Up-slope values were 
observed to be related to volume, velocity and peak image intensity. Hence, it was 
determined that the slope alone is not sufficient for quantitative flow analysis, even 
if it can be accurately obtained. In other words, the time-intensity technique can 
only be applied for relative flow analysis if no additional information on the volume 
or the flow rate is available. For example, it was assumed that the volume in both 
the phantoms is fixed and, thus, that the time constant is inversely proportional to 
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the volume flow rate distance by velocity. The estimation of the volume was 
reasonably accurate for the both phantom for a volume up to 50 mm3. Such 
information is expected to be critical in clinical applications of the time-intensity-
based quantitative flow analysis techniques. Alternatively, if the volumetric flow 
rate can be obtained by other techniques (e.g., conventional Doppler techniques), 
then the effective volume can be calculated. The derived volume may be further 
directly related to perfusion of a particular organ. 
In the flow phantoms, the signal intensity increased in flow rate from 10 
mL/min to 30 mL/min; further increase of flow-rate did not lead to any increase of 
the signal intensity. The results showed that the intensity increased by 
approximately 3 X as a function of dose increase from 10 to 30 mL/min. Further 
increase of the dose did not have influence on the intensity; in fact, a slight decrease 
of the intensity was observed. A possible explanation for these phenomena is 
microbubble saturation. This effect occurs when UCA microbubbles are too close 
together and multipath reverberations minimize backscatter signal. 
A significant increase in ultrasound intensity was observed as flow-rate was 
increased from 10 mL/min to 30 mL/min. The flow-rates beyond 30mL/min did not 
lead to further increase of the intensity. Using low flow-rates, the intensity was of 
particular interest, describing the indicator volume in the microcirculation. The 
intensity shows a high variation, but no systematic change by increasing flow rates 
in the range from 30 to 50 mL/min. These results were in correspondence with the 
dye-dilution theory, where the intensity was directly related to the contrast volume 
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because the amount of vessels in the flow phantom was not changed during the 
experiment. 
In the results with tumor vessel phantoms, measurement of both the in-flow 
and the out-flow of the ROI was found to be problematic, and may prove to be 
practically difficult in clinical situations using standard linear imaging probes. In 
other words, it may be difficult to place both the artery and the vein of an organ in 
the same image plane. Thus, 3-D imaging may be beneficial in generating the 
input/output time intensities.  Another complication is that many organs have 
multiple input vessels and multiple output vessels (e.g., liver and brain). Thus, the 
single input/single output model used in this paper also needs to be modified.  
107 
 
CHAPTER V 
Conclusions & Recommendations 
 
5.1 CONCLUSIONS 
Through past research it has been discovered that conventional flow phantoms are 
not easily reproducible and prohibitively difficult or impossible alternative to 
construct. Although many synthetic materials have been used, vascular flow 
phantoms have yet to be researched as a possible system to create realistic three-
dimensional flow and vascular structure to promote research for evaluations of 
cancer treatments and research in pre-clinical settings.  
In this study three types of vascular flow phantoms were developed and 
studied for the quantification of blood flow. After successful fabrication of the agar-
tissue mimic material within the concept of wall-less vessels, the time-intensity 
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curves were determined and average slope; mean intensity and average velocity of 
the flow was derived. Average pore size, scaffold porosity and water up taking 
capacity were analyzed and found to be comparative to porous scaffold used 
previously in research that promote cellular adhesion, proliferation and 
differentiation for tissue engineering application. In addition, the flow-rates were 
tested to investigate the slope of the intensities. The correlation coefficient between 
the mean slope measurements and the least squares fitted line was all higher than 
0.95, indicating a good linear relationship between the mean slope and the flow-
rates. For all single-vessel flow phantom data, the mean proportional difference of 
the slope measurements and flow-rate was +0.695 ± 0.18 (mean ± SD).  
 It was found that the correlation coefficient between the mean slope measurements 
and the least squares fitted line is 0.90, indicating a good linear correlation between 
the single-vessel and Multi-vessel flow phantoms. However, the parameters 
obtained from tumor region 1, 2 and 3 did not show any significant flow pattern and 
correlation after contrast injection of UCAs.  
Finally, the measured intensity at the tumor regions is used to represent 
concentration in this study. Although such an assumption has been used in many 
previous studies, some studies have also demonstrated the nonlinear relationship 
between the bubble concentration and the measured intensity. Thus, the initial 
concentration of the bolus injection needs to be carefully controlled. Otherwise, the 
linear system model will not be valid. More information can be obtained when 
intensities at both the input and the output are measured. For further studies, time 
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intensities acquired at the input vessel and the output vessel may also be correlated 
with the perfusion measurements acquired directly from the mixing chamber. 
Again, alternative modeling of the problem is required because such a flow system 
has multiple input vessels and multiple output vessels. Developing new time-an 
intensity-based technique is the focus of current research.  
 
 
5.2 RECOMMENDATIONS 
While the phantom generation technique presented herein is a novel means 
to more accurately construct microvasculature flow phantoms for ultrasound 
imaging studies, there are several improvements of the technique worth noting. 
First and foremost, it must be implemented in a water bath, as the tube needs a 
smooth acoustically transparent medium through which to move. This then makes it 
necessary to add speckle noise as a post-processing step if one is interested in 
analyzing vessels in a more realistic imaging context. Since the process of building 
up vessel networks presented in this manuscript is via simple vessel mold retraction 
in a wall-less agar, the signal to noise ratio (SNR) between the vessels and the 
background noise in the final composite vessel images is spatially variant as a 
function of how many vessel signals are added together at a given location. The 
noise power increases uniformly throughout the image volume of the composite 
vessel phantom as each individual vessel phantom is added to the composite image; 
the signal power within the vessels does not always increase at all locations, 
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however. In some locations of a composite image multiple vessels can be present, 
such as in the region before a bifurcation, and thus when they are added the final 
“vessel signal” increases N times (where N is the number of vessels present at a 
location). After vessels bifurcate and trace unique trajectories through the image 
space, their signals do not add any longer and thus are reduced relative to the 
increased noise power. While this was not accounted for in these preliminary proof-
of-concept imaging studies, one could compensate for this by characterizing the 
noise of the imaging system and normalizing the noise to the vessel signals in a post-
processing step after the composite vessel networks had been constructed, as the 
centerlines of each vessel within the network are known. 
An additional recommendation to improve the phantom generation 
technique is if one is interested in achieving non-trivial velocity streamlines within a 
vessel phantom generated by the method presented herein; additional degrees of 
freedom must be added to their experimental apparatus. For instance, if one wanted 
to simulate a change in flow direction at a bifurcation they would need to rotate the 
transducer relative to the tube at the appropriate location along the vessel’s 
centerline (or equivalently: rotate the tube beneath the transducer). This would 
become increasingly difficult in situations where a vessel’s trajectory varied in both 
the X and Y dimensions. As the transducer would need to undergo two independent 
rotations. While not impossible, it is likely that this type of imaging procedure would 
be prohibitively difficult. Thus, we propose this phantom generation method as 
primarily of interest for those interested in assessing complex vessel morphology.
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APPENDIX 
(A) Graphical Results of Single-vessel Flow phantom 
Imaging plane: Longitudinal, Flow-rate: 10mL/min, B-mode image: ROI 
 
Imaging plane: Longitudinal, Flow-rate: 10mL/min, time-intensity curve 
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Imaging plane: Longitudinal, Flow-rate: 10mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 10mL/min, B-mode image: ROI 
 
136 
 
Imaging plane: Lateral, Flow-rate: 10mL/min, time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 10mL/min, Slope 
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Imaging plane: Longitudinal, Flow-rate: 20mL/min, B-mode image: ROI 
 
Imaging plane: longitudinal, Flow-rate: 20mL/min, time-intensity curve 
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Imaging plane: Longitudinal, Flow-rate: 20mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 20mL/min, B-mode image: ROI 
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Imaging plane: Lateral, Flow-rate: 20mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 20mL/min, Slope 
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Imaging plane: Longitudinal, Flow-rate: 30mL/min, B-mode image: ROI 
Imaging plane: Longitudinal, Flow-rate: 30mL/min, B-mode image: time-intensity 
curve 
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Imaging plane: Longitudinal, Flow-rate: 30mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 30mL/min, B-mode image: ROI 
 
142 
 
Imaging plane: Lateral, Flow-rate: 30mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 30mL/min, Slope 
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Imaging plane: Longitudinal, Flow-rate: 40mL/min, B-mode image: ROI 
Imaging plane: Longitudinal, Flow-rate: 40mL/min, B-mode image: time-intensity 
curve 
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Imaging plane: Longitudinal, Flow-rate: 40mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 40mL/min, B-mode image: ROI 
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Imaging plane: Lateral, Flow-rate: 40mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 40mL/min, Slope 
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Imaging plane: Longitudinal, Flow-rate: 50mL/min, B-mode image: ROI 
 
Imaging plane Longitudinal, Flow-rate: 50mL/min, B-mode image: time-intensity 
curve 
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Imaging plane: Longitudinal, Flow-rate: 50mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 50mL/min, B-mode image: ROI 
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Imaging plane: Lateral, Flow-rate: 50mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 50mL/min, Slope 
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(B) Graphical Results of Multi-vessel Flow phantom 
Imaging plane: Longitudinal, Flow-rate: 10mL/min, B-mode image: ROI 
 
Imaging plane: Longitudinal, Flow-rate: 10mL/min, B-mode image: time-intensity 
curve 
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Imaging plane: Longitudinal, Flow-rate: 10mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 10L/min, B-mode image: ROI 
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Imaging plane: Lateral, Flow-rate: 10mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 10mL/min, Slope 
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Imaging plane: longitudinal, Flow-rate: 20mL/min, B-mode image: ROI 
 
Imaging plane: longitudinal, Flow-rate: 20mL/min, B-mode image: time-intensity 
curve 
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Imaging plane: longitudinal, Flow-rate: 20mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 20mL/min, B-mode image: ROI 
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Imaging plane: Lateral, Flow-rate: 20mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 20mL/min, Slope 
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Imaging plane: Longitudinal, Flow-rate: 30mL/min, B-mode image: ROI 
Imaging plane: Longitudinal, Flow-rate: 30mL/min, B-mode image: time-intensity 
curve 
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Imaging plane: Longitudinal, Flow-rate: 30mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 30mL/min, B-mode image: ROI 
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Imaging plane: Lateral, Flow-rate: 30mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 30mL/min, Slope 
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Imaging plane: longitudinal, Flow-rate: 40mL/min, B-mode image: ROI 
Imaging plane: longitudinal, Flow-rate: 40mL/min, B-mode image: time-intensity 
curve 
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Imaging plane: longitudinal, Flow-rate: 40mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 40mL/min, B-mode image: ROI 
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Imaging plane: Lateral, Flow-rate: 40mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 40mL/min, Slope 
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Imaging plane: longitudinal, Flow-rate: 50mL/min, B-mode image: ROI 
 
Imaging plane: longitudinal, Flow-rate: 50mL/min, B-mode image: time-intensity 
curve 
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Imaging plane: longitudinal, Flow-rate: 50mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 50mL/min, B-mode image: ROI 
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Imaging plane: Lateral, Flow-rate: 50mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 50mL/min, Slope 
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(A) Graphical Results of Tumor- vessel Flow phantom Tumor region 1 
Imaging plane: longitudinal, In-Flow-rate: 10mL/min, B-mode image: ROI 
 
Imaging plane: longitudinal, In-Flow-rate: 10mL/min, B-mode image: time-intensity 
curve 
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Imaging plane: longitudinal, In-Flow-rate: 10mL/min, Slope 
 
Imaging plane: Lateral, In-Flow-rate: 10mL/min, B-mode image: ROI 
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Imaging plane: Lateral, In-Flow-rate: 10mL/min, B-mode image: time-intensity 
curve 
 
Imaging plane: Lateral, Flow-rate: 10mL/min, Slope 
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Imaging plane: longitudinal, In-Flow-rate: 20mL/min, B-mode image: ROI 
 
Imaging plane: longitudinal, In-Flow-rate: 20mL/min, B-mode image: time-intensity 
curve 
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Imaging plane: longitudinal, In-Flow-rate: 20mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 20mL/min, B-mode image: ROI 
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Imaging plane: Lateral, Flow-rate: 20mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 20mL/min, Slope 
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Imaging plane: Longitudinal, Flow-rate: 30mL/min, B-mode image: ROI 
 
Imaging plane: Longitudinal, In-Flow-rate: 30mL/min, B-mode image: time-
intensity curve 
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Imaging plane: Longitudinal, In-Flow-rate: 30mL/min, Slope 
 
Imaging plane: Lateral, In-Flow-rate: 30mL/min, B-mode image: ROI 
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Imaging plane: Lateral, Flow-rate: 30mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 30mL/min, Slope 
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Imaging plane: Longitudinal, In-Flow-rate: 40mL/min, B-mode image: ROI 
 
Imaging plane: Longitudinal, In-Flow-rate: 40mL/min, B-mode image: time-
intensity curve 
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Imaging plane: Longitudinal, In-Flow-rate: 40mL/min, Slope 
 
Imaging plane: Lateral, in-Flow-rate: 40mL/min, B-mode image: ROI 
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Imaging plane: Lateral, In-Flow-rate: 40mL/min, B-mode image: time-intensity 
curve 
 
Imaging plane: Lateral, In-Flow-rate: 40mL/min, Slope 
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Imaging plane: Longitudinal, In-Flow-rate: 50mL/min, B-mode image: ROI 
Imaging plane: Longitudinal, In-Flow-rate: 50mL/min, B-mode image: time-
intensity curve 
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Imaging plane: Longitudinal, In-Flow-rate: 50mL/min, Slope 
 
Imaging plane: Lateral, In-Flow-rate: 50mL/min, B-mode image: ROI 
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Imaging plane: Lateral, In-Flow-rate: 50mL/min, B-mode image: time-intensity 
curve 
 
Imaging plane: Lateral, Flow-rate: 50mL/min, Slope 
 
179 
 
Imaging plane: Lateral, Out-Flow-rate: 10mL/min, B-mode image: ROI 
 
Imaging plane: Lateral, Out-Flow-rate: 10mL/min, B-mode image: time-intensity 
curve 
 
180 
 
Imaging plane: Lateral, Out-Flow-rate: 10mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 10mL/min, B-mode image: ROI 
 
181 
 
Imaging plane: Lateral, Flow-rate: 10mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 10mL/min, Slope 
 
182 
 
Imaging plane: Lateral, Out-Flow-rate: 20mL/min, B-mode image: ROI 
Imaging plane: Lateral, Out-Flow-rate: 20mL/min, B-mode image: time-intensity 
curve 
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Imaging plane: Lateral, Out-Flow-rate: 10mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 20mL/min, B-mode image: ROI 
 
184 
 
Imaging plane: Lateral, Flow-rate: 20mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 10mL/min, Slope 
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Imaging plane: Longitudinal, Out-Flow-rate: 30mL/min, B-mode image: ROI 
 
Imaging plane: Longitudinal, Out-Flow-rate: 30mL/min, B-mode image: time-
intensity curve 
 
186 
 
Imaging plane: Longitudinal, Out-Flow-rate: 30mL/min, Slope 
 
Imaging plane: Lateral, Flow-rate: 30mL/min, B-mode image: ROI 
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Imaging plane: Lateral, Flow-rate: 30mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 30mL/min, Slope 
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Imaging plane: Longitudinal, Out-Flow-rate: 40mL/min, B-mode image: ROI 
 
Imaging plane: Longitudinal, Out-Flow-rate: 40mL/min, B-mode image: time-
intensity curve 
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Imaging plane: Longitudinal, Out-Flow-rate: 40mL/min, Slope 
 
 
Imaging plane: Lateral, Flow-rate: 40mL/min, B-mode image: ROI 
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Imaging plane: Lateral, Flow-rate: 40mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 40mL/min, Slope 
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Imaging plane: Longitudinal, Out-Flow-rate: 50mL/min, B-mode image: ROI 
 
Imaging plane: Longitudinal, Out-Flow-rate: 20mL/min, B-mode image: time-
intensity curve 
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Imaging plane: Longitudinal, Out-Flow-rate: 10mL/min, Slope 
 
 
Imaging plane: Lateral, Flow-rate: 50mL/min, B-mode image: ROI 
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Imaging plane: Lateral, Flow-rate: 50mL/min, B-mode image: time-intensity curve 
 
Imaging plane: Lateral, Flow-rate: 50mL/min, Slope 
 
